Investigating the by-stander effect of Hypericin induced photodynamic therapy on human skin cells by Popovic, Ana
Un
ive
rsi
ty 
of 
Ca
pe
 T
ow
n
1 
 
Investigating the By-Stander Effect of 
Hypericin Induced Photodynamic 
Therapy on Human Skin Cells 
 
By: 
Ana Popovic 
PPVANA001 
 
Submitted to the University of Cape Town  
In fulfilment of the requirements for the degree 
 
MSc (Med) in Cell Biology 
 
Date of Submission: 18 August 2014 
Supervisor: Dr Lester M. Davids 
 
Department of Human Biology 
Faculty of Health Sciences 
University of Cape Town 
 
The copyright of this thesis vests in the author. No 
quotation from it or information derived from it is to be 
published without full acknowledgement of the source. 
The thesis is to be used for private study or non-
commercial research purposes only. 
Published by the University of Cape Town (UCT) in terms 
of the non-exclusive license granted to UCT by the author. 
Un
ive
rsi
ty 
f C
ap
e T
ow
n
2 
 
Plagiarism Declaration 
 
I, ………………………………, hereby declare that the work on which this 
dissertation/thesis is based is my original work (except where 
acknowledgements indicate otherwise) and that neither the whole work nor 
any part of it has been, is being, or is to be submitted for another degree in 
this or any other university. 
I empower the university to reproduce for the purpose of research either the 
whole or any portion of the contents in any manner whatsoever. 
 
Signature: ………………………………… 
 
Date:   ………………………
3 
 
 
Contents 
Plagiarism Declaration ......................................................................................2 
Acknowledgements: .............................................. Error! Bookmark not defined. 
List of Abbreviations .........................................................................................6 
List of Figures and Tables ................................................................................6 
Abstract ............................................................................................................ 11 
Chapter 1: Literature Review .......................................................................... 13 
1.1. The Skin 13 
1.2. Skin Cancer 17 
1.2.1. Skin Cancer Statistics 17 
1.2.2. Causes of Skin Cancer 18 
1.2.3. Skin Cancer Types 19 
1.2.4. Skin Cancer Treatment 20 
1.3. Photodynamic Therapy 21 
1.3.1. The Principles of Photodynamic therapy (PDT) 21 
1.3.2. PDT Efficacy and Outcome: Photosensitisers 24 
1.3.3. PDT Efficacy and Outcome: Light Source Activation 27 
1.4. The Photochemical and Photophysical Properties of Hypericin 29 
1.5. Hypericin Uptake and Localization 32 
1.6. Cytotoxic Effects of Hypericin-Induced Photodynamic Therapy 33 
1.7. HYP-PDT Induced Apoptosis 34 
1.8. HYP-PDT and Prosurvival Effects 36 
1.9. HYP-PDT and In Vitro Skin Cancer Studies 37 
1.10. HYP-PDT and In Vivo Skin Cancer Studies 39 
1.11. The Bystander Effect of HYP-PDT on Normal Cells 40 
1.12. Aims 41 
4 
 
Chapter 2: Materials and Methods ................................................................. 43 
2.1. In Vitro Human Skin Cell Culture Model 43 
2.1.1. Isolation of Primary Human Skin Cells 43 
2.1.2. Tissue Culture Conditions 44 
2.1.3. Growth Curves 45 
2.2. Photodynamic Therapy (PDT) 45 
2.2.1. Hypericin Preparation 45 
2.2.2. Laser Light Activation 46 
2.2.3. Hypericin Induced Photodynamic Therapy (HYP-PDT) 47 
2.3. Cell Viability Assay 48 
2.4. Reactive Oxygen Species (ROS) Assay 49 
2.5. Cell Morphology Analysis 50 
2.6. Apoptosis Analysis 51 
2.7. Data Analysis 55 
2.8. Methods Summary 56 
Chapter 3: Results ........................................................................................... 57 
3.1 Growth Dynamics of Primary Human Skin Cells 57 
3.2 Cell Viability 24 Hours Post HYP-PDT 60 
3.3 Cell Morphology 24 Hours Post HYP- PDT 63 
3.4 Intracellular ROS levels 30 Minutes Post HYP-PDT 72 
3.5 Cell Death Analysis 24 Hours Post HYP-PDT 73 
Chapter 4: Discussion: .................................................................................... 76 
4.1 Primary Human Skin Cells Have Different Growth Dynamics in 
Culture                                                                                                           77 
4.2 HYP-PDT Induces Differential Cytotoxicity in Primary Human Skin 
Cells                                                                                                           78 
4.3 HYP-PDT Induces Distinct Morphological Changes in Primary 
Human Skin Cells 24 hours post Treatment 80 
5 
 
4.4 HYP Localizes Perinuclearly in Primary Human Skin Cells 81 
4.5 HYP-PDT Increased Intracellular ROS Levels in Fb but not in Kc or 
Mc                                                                                                           81 
4.6 Conclusions and Future Directions 84 
References ....................................................................................................... 87 
Appendix A: Solutions .................................................................................. 104 
 
6 
 
List of Abbreviations 
ALA 5-Aminolevunilic acid 
AKT/PKB Protein Kinase B 
AP-1 Activator protein 1 
ARF Human ADP-ribosylation factor protein 
BCC Basal cell carcinoma 
BAK Bcl2 homologous antagonist killer 
Bcl-2 B-cell lymphoma 2 
Bid BH3 interacting-domain death agonist 
bFGF Basic fibroblast growth factor 
BRAF V-raf murine sarcoma viral oncogene homolog B1 
COX2 Cyclooxygenase 
Cyt C Cytochrome C 
CDKN2A Cyclin dependent kinase 2A 
DAMPS Damage associated molecular patterns 
DCF Dichlorofluoroscein 
DCF-DA 2’ 7’ –dichlorofluorescein diacetate 
DMEM Dulbecco’s Modified Eagles Medium 
DMSO Dimethyl Sulfoxide 
DOPA Dihydroxyphenylalanine 
ECM Extracellular matrix 
ER Endoplasmic reticulum 
ERK Extracellular signal regulated kinase 
FACS Fluorescent activated cell sorting 
FADD Fas associated death domain protein 
FASL Fas ligand 
Fb Primary human fibroblasts 
FCS Fetal Calf Serum 
FDA Food and Drug Administration 
FETI Melanocyte specific medium 
GREENS Keratinocytes maintenance medium 
HDL High density lipoproteins 
7 
 
HpD Hematoporphyrin derivative 
HYP Hypericin 
HYP-PDT Hypericin induced photodynamic therapy 
J/cm2 Joules per surface unit of area 
JNK 1 c-Jun N-terminal kinase 1 
Kc Primary human keratinocytes 
KSFM Keratinocyte specific medium 
LD50 Lethal dose 
LDL Low density lipoproteins 
MAL Methyl-aminolevunilic acid 
MAPK Mitogen activated protein kinase 
Mc Primary human melanocytes 
MEK Mitogen-activated protein/extracellular signal-regulated 
kinase 
mins Minutes 
MITF Microphthalmia-associated transcription factor 
MMP2 Matrix metalloproteinase 2 
Nd: YAG neodymium-doped yttrium aluminium garnet 
NMSC Non-melanoma skin cancer 
1O2 Singlet oxygen 
P38MAPK P38 Mitogen activated protein kinase 
P16INK2A Cyclin-dependent kinase inhibitor 2A, multiple tumor 
suppressor 1 
PARP Poly (ADP-ribose) polymerase 
PBS Phosphate buffered saline 
PDT Photodynamic therapy 
PFA Paraformaldehyde 
PI Propidium iodide 
PIP 3 Phosphatidylinositol -3-trisphosphate 
PKC Protein kinase C 
PTCH1 Protein patched homolog 1 
PTEN Phosphatase and tensin homolog 
PVP Polyvinylpyrrolidone 
8 
 
RAS Rat sarcoma tumor suppressor protein 
RGP Radial growth phase 
ROS Reactive oxygen species 
s Seconds 
SCC Squamous cell carcinoma 
SERCA 2 Sacro/endoplasmic Ca2+ ATPase 2 
SOD Superoxide dismutase 
TGF- β Transforming growth factor β 
TNF-α Tumor necrosis factor α 
TP53 Tumor protein p53 
TRAIL Tumor necrosis factor-related apoptosis inducing ligand 
TRPM1 Transient receptor potential cation channel subfamily M 
member 1 
mW Milli Watts 
UVR Ultraviolet radiation 
VGP Vertical growth phase 
W Watts 
W/cm2 Watts per surface unit of area 
XTT Cell proliferation kit II 
 
9 
 
List of Figures and Tables 
Chapter 1: Literature Review 
 
Figure 1.1.1 Cross section of human skin 18 
Figure 1.3.1 The basic principles of PDT 25 
Table 1.3.2 Photosensitisers Currently Used During Clinical 
PDT 
29 
 
Figure 1.3.4 Hypericin chemical and physical properties 31 
Figure 1.3.7 The Mechanism of Apoptosis 38 
   
Chapter 2: Material and Methods 
 
Table 2.2.1 Laser Parameters Used to Calculate Irradiating 
Time 
49 
Figure 2.6.1 Percentage of negative events in the PE-A 
channel 
55 
Table 2.6.1 Mean Fluorescent Intensities of the PE-A 
channel 
56 
   
Chapter 3: Results 
 
Figure 3.1.1 Growth curves of primary human skin cells 59 
Table 3.1.1 Characteristics of primary human skin cells 60 
Figure 3.2.1 Cell viability of primary human skin cells 63 
Figure 3.3.1 Cell morphology of Fb 24 hours post HYP-PDT 66 
Figure 3.3.2 Cell morphology of Mc 24 hours post HYP-PDT 69 
Figure 3.3.3 Cell morphology of Kc 24 hours post HYP-PDT 71 
Figure 3.4.1 Intercellular ROS levels post HYP-PDT in 
primary human skin cells 
73 
Figure 3.5.1 Apoptosis analysis in primary human skin cells 
24 hours post HYP-PDT 
76 
   
10 
 
Chapter 4: Discussion 
 
Figure 4.6.1 Summary of results and future directions 87 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
11 
 
Abstract 
Skin cancer is the most common cancer worldwide, and its incidence rate in 
South Africa is increasing. Photodynamic therapy (PDT) has been shown to 
be an effective treatment modality, through topical administration, for 
treatment of non-melanoma skin cancers. Our group investigates hypericin-
induced PDT (HYP-PDT) for the treatment of both non-melanoma and 
melanoma skin cancers. However, a prerequisite for effective cancer 
treatments is efficient and selective targeting of the tumoral cells with minimal 
collateral damage to the surrounding normal cells, as it is well know that 
cancer therapies have bystander effects on normal cells in the body, often 
causing undesirable side effects.  
 
PDT can induce a bystander effect, defined as indirect damaged induced into 
adjacent cells either via intercellular gap junctions or via diffusible ROS 
released in the microenvironment. It is therefore important to know the effects 
of HYP-PDT on the normal cell population surrounding the non-melanoma 
skin cancer or melanoma tumor. The aim of this project was to investigate 
the cellular and molecular effects of HYP-PDT on normal primary human 
keratinocytes (Kc), melanocytes (Mc) and fibroblasts (Fb) in an in vitro tissue 
culture model thus representing both the epidermal and dermal cellular 
compartments of human skin.  
 
Cell viability and morphology analysis revealed a differential cytotoxic 
response to a range of HYP-PDT doses in all the human skin cell types. Fb 
were the most susceptible followed by Mc and then Kc. Fb cell viability was 
significantly different post 1µM (56%) (p<0.001); 2µM (48%) (p<0.001); 3µM 
(33%) (p<0.001) and 4µM (43%) (p<0.001) HYP-PDT. Similarly, distinct 
changes in Fb morphology were observed after a non-lethal (1µM) and lethal 
(3µM) dose of HYP-PDT.  However, Mc were less susceptible than Fb to 
HYP-PDT doses, displaying significant differences in cell viability occurring at 
2µM (60%) (p<0.05); 3µM (61%) (p<0.05) and 4µM (38%) (p<0.001). Distinct 
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changes in Mc morphology were also observed at both a non-lethal (1µM) 
and lethal (3µM) HYP-PDT dose. In contrast, Kc were the least sensitive to 
HYP-PDT compared to Mc and Fb as an initial significant difference in cell 
viability (79%) (p<0.05) only occurred at a dose of 4µM hypericin without 
causing significant morphological changes in Kc cellular integrity. Fluorescent 
microscopy displayed peri-nuclear localization of HYP in all the cell types and 
HYP was excluded from the nucleus of all 3 cell types.  
 
Intracellular ROS levels measured in Fb at 3µM HYP-PDT, displayed a 
significant 3.8 fold (p<0.05) increase in ROS, but no significant difference in 
ROS levels occurred in Mc or Kc. Furthermore, 64% (p<0.005) early 
apoptotic Fb and 20% (p<0.05) early apoptotic Mc were evident; using 
fluorescence activated cell sorting (FACS), 24 hours post 3µM HYP-PDT. 
These results depict a differential response to HYP-PDT by different human 
skin cells suggesting an awareness of the efficacy and indeed, the bystander 
effect, when HYP-PDT is administered.  Future directions include 
investigating whether the tumor microenvironment affects skin cancer cell 
response to HYP-PDT which contributes to improved targeting of tumor cells 
and sparing peri-tumoral normal cells. 
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Chapter 1: Literature Review 
1.1. The Skin 
The human body’s largest organ is the skin (Figure 1.1.1 A), which has 
several important physiological functions regulating body temperature; 
protecting the body from mechanical and chemical stress and defending the 
body from pathogens in the external environment (Tobin, 2006). Human skin 
consists of two main layers (Figure 1.1.1 A) that are separated by the 
basement membrane: the superficial epidermis and the deeper dermis; with 
the subcutaneous fat layer (hypodermis) situated beneath the dermis (Powell 
& Soon, 2002; Tobin, 2006). The epidermis is architecturally arranged in 4 
tiers named: the outermost stratum corneum, the stratum granulosum, the 
stratum spinosum and the startum basale (Powell & Soon, 2002; Tobin, 
2006). These 4 tiers are populated primarily by keratin-producing 
keratinocytes that become increasingly more differentiated towards the 
stratum corneum layer.  Some examples of keratins include: cell proliferation 
associated keratins (K5 and K14) and keratins which are expressed by 
differentiated keratinocytes (K1, K2, K10, K11) (Tobin, 2006).  
 
In the stratum basale, residing on the basement membrane are pigment 
producing melanocytes (Figure 1.1.1 B) which extend their dendrites to 
several keratinocytes (Tobin 2006; Ortonne 2002). The ratio of melanocytes 
to keratinocytes in the epidermis is: 1:36 but in the basal layer, the dendrites 
of 1 melanocytes associate with approximately 5 keratinocytes (Haass & 
Herlyn, 2005).  Melanocytes produce the body’s endogenous sunscreen 
called melanin which is synthesized and stored in specialized organelles 
called melanosomes (Hearing, 2005; Ortonne, 2002; Thompson, Scolyer, & 
Kefford, 2005). Melanin is synthesized through a process called 
melanogenesis that involves the hydroxylation of tyrosine to 
dihydroxyphenylalanine (DOPA) by the rate limiting enzyme tyrosinase 
(Ortonne, 2002). Thereafter, DOPA is further oxidized to dopaquinone, a 
melanin precursor that yields the two different types of melanin: eumelanin –
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black to brown and pheomelanin -yellow to reddish brown (Hearing, 2005; 
Ortonne, 2002).  
 
Melanin not only attributes skin colour but also acts as an ultraviolet radiation 
(UVR) filter (Ortonne, 2002). Melanin-filled melanosomes are then 
transferred to keratinocytes via melanocyte dendrites and the melanin 
accumulates as a perinuclear cap in keratinocytes, thereby acting as a shield 
that absorbs and reflects UVR; preventing DNA damage (Hearing, 2005; 
Ortonne, 2002). Melanosomal transfer from melanocytes to keratinocytes can 
occur via several different mechanisms such as individual release of 
melanosomes from melanocyte dendrites which are taken up via 
phagocytosis by keratinocytes, membrane fusion of the two cell types; via 
filapodia extended from both cell types or via the shedding vesicle system 
(Ando et al., 2012; Mottaz & Zelickson, 1967; Scott, Leopardi, Printup, & 
Madden, 2002; Seiberg, 2001).  Melanin is responsible for UVR-induced skin 
tanning and  is an excellent free radical scavenger/antioxidant (Ortonne, 
2002).  
 
Other cell types present in the epidermis are immune Langerhans cells and 
nerve Merkel cells (Tobin, 2006). The basement membrane, which separates 
the epidermal and dermal layers, is made up of molecules that promote cell 
adhesion such as integrins, laminins and collagens (IV and VII), that also 
regulate keratinocyte migration from the stratum basale during processes 
such as wound healing (Powell & Soon, 2002; Tobin, 2006). 
 
The dermis consists of fibroblasts interspersed in a dense amorphous extra 
cellular matrix (ECM), containing mostly collagen molecules (Frantz, Stewart, 
& Weaver, 2010; Tobin, 2006). To a lesser extent, the following glycoproteins 
also contribute to the ECM: fibronectin, elastin, laminin,  fibrilin and TGF-β 
binding proteins (Frantz et al., 2010; Tobin, 2006). ECM proteins not only 
provide the skin with structural integrity, but are also important mediators of 
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cellular migration, adhesion and intercellular signaling (Frantz et al., 2010; 
Tobin, 2006). Fibroblasts are migratory cells that synthesize and degrade 
collagen and most of the ECM components, thereby shaping the dense 
fibrous and elastic meshwork of the dermis (Frantz et al., 2010; Tobin, 2006). 
Blood vessels, nerves, nerve receptors lymphatics, hair follicles, sebaceous 
glands and sweat glands are also situated in the dermis (Tobin, 2006). 
Therefore, the human skin is designed to protect the internal body from 
mechanical and external stresses especially, UVR which is a DNA damaging 
agent (Ortonne, 2002; Tobin, 2006). 
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A) 
 
 
(http://kids.britannica.com/elementary/art-89672/Human-skin-has-three-
layers-the-epidermis-the-dermis-and) 
B)  
(http://droualb.faculty.mjc.edu/Lecture%20Notes/Unit%201/Integument
ary%20with%20figures.html) 
Figure 1.1.1: Cross section of human skin (A); Melanocyte and keratinocyte 
interaction at the basement membrane in the epidermis (B)  
 
 
17 
 
1.2. Skin Cancer  
1.2.1. Skin Cancer Statistics 
Skin cancer is the third most frequent malignancy in the world. It is 
subdivided into  non-melanoma skin cancer (NMSC) and melanoma (Gray 
Schopfer et al., 2007). NMSC is the most common skin cancer type, 
accounting for 95% of all skin cancers with an estimated 2-3 million cases of 
NMSC occurring per year (Ahmed, Soyer, Saunders, Boukamp, & Roberts, 
2008; Narayanan, Saladi, & Fox, 2010). Although rarely fatal, NMSC often 
results in aesthetic disfigurement, especially on the head, face and neck 
(Ahmed et al., 2008).  
 
Melanoma, although only accounting for 5% of  all skin cancers, has the 
greatest potential to metastasize and is responsible for approximately 85% of 
skin cancer related deaths (A. J. Miller & Mihm, 2006; Thompson et al., 
2005). Shockingly,  the prognosis for an estimated 14% of patients with 
metastatic melanoma is 5 years or less (A. J. Miller & Mihm, 2006). 
Furthermore, the WHO has estimated that melanoma has the fastest growing 
incidence rate compared to all cancers: doubling every 10-20 years (Lens & 
Dawes, 2004). 
 
In a South African context, immuno-compromised patients are at a higher risk 
of getting NMSC (Lauth, Unden, & Toftgård, 2004). Subsequently, a  recent 
study showed that HIV+ subjects had a two times higher incidence rate of 
NMSC compared to HIV- subjects (Silverberg et al., 2013). It is therefore 
concerning that the incidence rate of both NMSC and melanoma is 
increasing each year (Ahmed et al., 2008; Lens & Dawes, 2004; Thompson 
et al., 2005). 
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1.2.2. Causes of Skin Cancer  
The predominant cause of skin cancer is ultraviolet radiation (UVR) which 
comprises UVA (315-400nm), UVB (280- 315nm) and UVC (100 – 280nm) 
wavelengths (de Gruijl, van Kranen, & Mullenders, 2001; Narayanan et al., 
2010; Pfeifer & Besaratinia, 2012). UVC is filtered by the ozone layer and 
does not reach the earth’s surface but UVA and UVB are able to penetrate 
the human skin and induce DNA damage and genetic mutations in human 
skin cells, thereby inducing skin cancer (Cadet, Mouret, Ravanat, & Douki, 
2012; de Gruijl et al., 2001; Narayanan et al., 2010; Pfeifer & Besaratinia, 
2012).  
 
UVB penetrates the epidermis and is the main mutagenic culprit, as it can 
directly damage DNA by inducing cyclobutane pyrimidine dimers primarily by 
C-T transitions (Ahmed et al., 2008; Cadet et al., 2012; Narayanan et al., 
2010). This results in CC to TT double base changes, known as the UVB 
signature; causing mutations in certain genes such as the tumor suppressor 
gene TP53 in keratinocytes (Ahmed et al., 2008; Cadet et al., 2012). 
 
UVA can penetrate both the epidermis and the dermis  and can indirectly 
cause DNA damage via reactive oxygen species (ROS) (Ahmed et al., 2008; 
Cadet et al., 2012; Narayanan et al., 2010; Pfeifer & Besaratinia, 2012). 
Moreover, UVA more likely than UVB,  causes DNA damage in basal 
keratinocytes in the stem-cell like layer at the basement membrane in the 
epidermis (Agar et al., 2004). 
 
Furthermore, UVR-induced DNA damage can directly cause gene mutations, 
deregulation in DNA repair mechanisms, aberrant apoptosis, immuno-
suppression, oxidative stress and stimulate the ECM to produce growth 
factors, thus promoting a cancer cell phenotype and a tumor 
microenvironment (Narayanan et al., 2010; Pfeifer & Besaratinia, 2012; 
Thompson et al., 2005). A skin cancer’s microenvironment has a stiff 
19 
 
architecture as a result of  ECM proteins and contains transformed 
fibroblasts, macrophages and T- lymphocytes (Celli, 2013; Frantz et al., 
2010; Quail & Joyce, 2013;  Vittar et al., 2013). Bidirectional communication 
exists between a cancer and its microenvironment which promotes 
angiogenesis, tumor proliferation, metastasis and tumor resistance (Frantz et 
al., 2010; Quail & Joyce, 2013; Vittar et al., 2013; Vittar et al., 2013) 
 
 
1.2.3. Skin Cancer Types 
NMSC presents either as basal cell carcinoma (BCC) or squamous cell 
carcinoma (SCC) and stems from mutations induced in keratinocytes 
however, due to genetic heterogeneity different genes can be mutated in 
keratinocytes  (Lauth et al. 2004; Melnikova & Ananthaswamy 2005). Eighty 
percent  of diagnosed skin cancers are BCC which is a slow growing and 
rarely metastatic keratinocyte derived cancer with mutations in the patched 
gene PTCH1 and  tumour suppressor TP53 gene (de Gruijl et al., 2001; 
Lauth et al., 2004; Melnikova & Ananthaswamy, 2005). SCC is more 
aggressive and less frequent (1:4) than BCC that may occasionally 
metastasize (Lauth et al., 2004). SCC occurs as a result of mutations in 
TP53; P16INK2A genes, AP1 transcription factor complex and the pro-
inflammatory cyclooxygenase (COX2) (Ahmed et al., 2008; Lauth et al., 
2004).  
 
Melanoma develops from genetic aberrations induced in melanocytes with 
the most common mutations  in the BRAF, N-RAS, CDKN2A and PTEN 
genes (Gray Schopfer et al., 2007; A. J. Miller & Mihm, 2006; Thompson et 
al., 2005). Other less common mutations which result in a carcinogenic 
phenotype include MEK, ERK, ARF, P53, AKT and MITF proteins (Gray 
Schopfer et al., 2007; A. J. Miller & Mihm, 2006). Due to these genetic 
mutations and  microenvironment changes, melanoma clonally expands in 
the epidermis; undertaking a radial form of clonal cellular expansion called 
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the  radial growth phase (RGP) (A. J. Miller & Mihm, 2006). Unattended, 
these cells grow even more aggressively and adopt a vertical growth 
dimension which breaches the basement membrane and invades the dermis. 
This phase is called the vertical growth phase (VGP). However, it has been 
stipulated in a review by (Damsky, Theodosakis, & Bosenberg, 2014) that the 
progression from the RGP to the VGP is a very complex process. The aim of 
the VGP phase is expansion of the clone towards the blood vessels in the 
dermis which allows the final metastatic phase and consequential 
dissemination into the blood (A. J. Miller & Mihm, 2006).  
 
During metastasis there is down regulation of certain adhesion molecules 
such as E-cadherin, Survivin and TRPM1 and upregulation of  N-cadherin, 
αVβ3 integrin and MMP2 (A. J. Miller & Mihm, 2006). Furthermore, there is 
some evidence that certain individuals have a genetic predisposition for 
melanoma susceptibility by inheriting a mutation in the CDKN2A gene which 
has been linked to a higher melanoma incidence rate, especially  in people 
who live at lower altitudes and experience high UVR exposure (Thompson et 
al., 2005). Although individuals with a fairer skin type, often with European 
ancestry, are more susceptible to skin cancer than individuals with darker 
(pigmented) skin, darker skinned individuals can get skin cancer and their 
prognosis is often unsatisfactory due to late presentation and late diagnosis 
(Bradford, 2009). 
 
1.2.4. Skin Cancer Treatment 
Once a NMSC or a melanoma is diagnosed the current, golden standard of  
treatment is surgical resection (Freak, 2004; Ross, Cherpelis, Lien, & 
Fenske, 2013; Zhao & He, 2010). Thereafter, patients with aggressive skin 
cancers such as melanoma are usually treated with bouts of adjuvant therapy 
including chemotherapy or ionizing radiation (Thompson et al., 2005). 
However, melanoma is often resistant to these traditional therapies which is 
reflected by its high recurrence rate , poor patient prognosis and multi-drug 
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resistance (L M Davids & Kleemann, 2010; Fukunaga-Kalabis & Herlyn, 
2012; Thompson et al., 2005). A need therefore exists for novel, adjuvant 
melanoma therapies (L M Davids & Kleemann, 2010).  
 
Photodynamic therapy (PDT) is a promising, potential therapy for melanoma 
(Baldea, Filip, & Napoca, 2012; L M Davids & Kleemann, 2010). 
Furthermore, it is an effective treatment modality offered clinically in some 
parts of Europe and the USA for the treatment of NMSC, especially in NMSC 
that occurs on sensitive areas of the face, head and neck which are difficult 
to resect (Ross et al., 2013; Wan & Lin, 2014; Zhao & He, 2010). PDT is a 
minimally invasive therapy that results in good cosmetic outcome which can 
also be applied topically on cancerous skin lesions (Agostinis et al., 2011; 
Brown, Brown, & Walker, 2004; Ross et al., 2013; Wan & Lin, 2014; Zhao & 
He, 2010). 
 
 
1.3. Photodynamic Therapy 
1.3.1. The Principles of Photodynamic therapy (PDT) 
PDT is a cancer treatment modality which is dependent on the interaction of 
light, a chemical compound know as a photosensitiser  and oxygen in the 
tumor microenvironment (Agostinis et al., 2011; Dolmans, Fukumura, & Jain, 
2003; Robertson, Evans, & Abrahamse, 2009). PDT was initially clinically 
used for the treatment of skin and bladder cancer in 1975 by Thomas 
Dougherty and in 1976 by J.F. Kelly, respectively. It was officially recognized 
as a cancer therapy in 1999, for the treatment of bladder cancer, upon FDA 
approval in Canada (Ackroyd, 2001; Dolmans et al., 2003). 
 
Currently, PDT is clinically used for the treatment of several cancers 
including bladder, lung, esophageal, breast, brain, head and neck, 
pancreatic, ophthalmic, prostate, liver, bile duct,  sarcoma, nasopharyngeal, 
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cutaneous T-cell lymphoma and BCC  (Agostinis et al., 2011; Brown et al., 
2004; Hopper, 2000). Furthermore, dermatologists not only use PDT 
routinely in clinics for the treatment of BCC but also for other dermatological 
conditions such as psoriasis and actinic keratosis (Ross et al., 2013; Zhao & 
He, 2010). However, the treatment of SCC and melanoma skin cancers is 
currently being investigated (Ross et al. 2013; Wan & Lin 2014; Morton et al. 
2008). Moreover, in South Africa, PDT is an emerging cancer therapy and is 
being offered to patients in some private practices. 
 
PDT involves the topical or systemic administration of a photosensitiser 
which upon light activation,  becomes excited and gains energy (Figure 1.3.1) 
resulting in an unstable molecule which must transfer an electron and release 
energy in order to return to the lower energy level and more stable ground 
state (Agostinis et al., 2011; Plaetzer, Krammer, Berlanda, Berr, & Kiesslich, 
2009; Stapleton & Rhodes, 2003). Therefore, the photosensitiser must 
release energy (Figure 1.3.1) by either donating an electron to a biomolecule 
(Type I) or to O2 molecules (type II) in the microenvironment (Castano et al, 
2004). These 2 photochemical reactions produce consequential intracellular 
reactive oxygen species (ROS) in the vicinity of photosensitiser activation 
and the type II reaction is most favored by photosensitizers due to 
thermodynamic laws and results in the formations of the highly reactive and 
short lived singlet oxygen (1O2) species (Calzavara-Pinton, Venturini, & Sala, 
2007; Castano et al., 2004). 1O2 is extremely unstable and can further 
transfer electrons and induce ROS-mediated lipid and protein peroxidation 
(Castano et al., 2004; Plaetzer et al., 2009).  
 
An accumulation of ROS in target cancer cells can cause damage to 
organelles, leading to multifaceted triggering of cell death pathways such as 
apoptosis, necrosis and autophagy, resulting in cancer cell death and 
subsequent tumour destruction (Agostinis et al., 2011; Plaetzer et al., 2009; 
Robertson et al., 2009). Furthermore, PDT may potentially infer anti -tumor 
immunity by eliciting the innate and adaptive immune response as well as 
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inducing anti-vascular effects by causing vasoconstriction in the tumour 
microenvironment (Agostinis et al., 2011; Castano, 2006). 
 
 
 
 
 
Figure 1.3.1: The basic principles of PDT (Karioti & Bilia, 2010) 
 
 
As a cancer therapy, PDT offers several advantages compared to current 
cancer therapies (Agostinis et al., 2011).  These include minimal 
invasiveness and high tumour specificity which can be attributed to 3 key 
factors:  photosensitizers are specifically bioengineered to target cancer 
cells; cytotoxic effects of photosensitizers are limited to the vicinity of their 
localization within a cell and the light dose during PDT can be directed to 
irradiate only the tumor tissue with the aid of improved photo-technology 
(Agostinis et al., 2011; Dolmans et al., 2003). Furthermore, PDT does not 
interfere with the outcome of other cancer therapies and can be used 
adjunctively with other therapies such as surgery and chemotherapy 
(Agostinis et al., 2011; Zhao & He, 2010). Additionally, PDT can be used to 
treat internal cancers of the body with repeated PDT doses which can be 
administered to outpatients in clinics as they do not require hospitalization 
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(Castano et al., 2004; Morton et al., 2008; Ross et al., 2013; Wan & Lin, 
2014).  Moreover, PDT of NMSC and other dermatological conditions ensues 
a good cosmetic outcome and PDT of internal insitu tumors results in  organ 
preservation (Brown et al., 2004; Ross et al., 2013). 
Despite, the advantages of PDT, its main disadvantage is that PDT is not 
currently used to treat patients with systemic and metastatic cancers 
because PDT has great cancer lesion specificity (Agostinis et al., 2011; 
Hopper, 2000). However, with the advancement in technology of  light 
delivery instruments; this disadvantage is becoming a possibility in the near 
future (Agostinis et al., 2011). Furthermore, some of the side effects 
associated with PDT of BCC are: pain, itching, edema, erythema and 
inflammation, epithelial abrasion, pustules and skin hyper pigmentation but 
there are currently investigations into the use of sunlight as a PDT light 
source to reduce pain and discomfort experienced by patients undergoing 
PDT of NMSC and Bowens disease (a form of SCC) (Wan & Lin 2014; Ross 
et al. 2013). 
 
 
1.3.2. PDT Efficacy and Outcome: Photosensitisers 
The synergistic actions of photosensitiser and light in the presence of O2, are 
required for successful PDT outcome (Agostinis et al., 2011; Dolmans et al., 
2003; Plaetzer et al., 2009). Investigating the ideal photosensitiser and its 
complimentary light source is therefore important as it may lead to improved 
PDT efficacy (Allison et al., 2004; Castano et al., 2004; Stapleton & Rhodes, 
2003; Zhao & He, 2010). 
 
Crucial characteristics of an ideal photosensitiser include high tumour 
selectivity, maximal and rapid accumulation, retention in cancer cells and an 
effective and fast clearance rate from the body (Allison et al., 2004; Detty, 
Gibson, & Wagner, 2004; Mojzisova, Bonneau, & Brault, 2007; Robertson et 
al., 2009). Ideally, the photosensitiser should be a single and chemically pure 
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compound which is inert and non-toxic in the dark that can be stored 
effectively (Agostinis et al., 2011; Castano et al., 2004; Mojzisova et al., 
2007). It is also important for the photosensitiser to have a have a high 
quantum yield, enabling it to generate sufficient 1O2 upon light absorption 
(Castano et al., 2004; Detty et al., 2004).  
 
The first FDA approved (1993) photosensitizer was intravenous 
hematoporphyrin derivative (HpD), known commercially as Photofrin®  
(Table 1.3.2) that was initially a water soluble mixture of porphyrins and is 
now used in a more purified form as porfimer sodium (Agostinis et al., 2011; 
Calzavara-Pinton et al., 2007; Mojzisova et al., 2007) However, Photofrin® 
demonstrated several clinical shortfalls including poor selectivity and 
specificity for tumors compared to normal tissue with patients experiencing 
prolonged light-sensitivity of the skin, lasting  between 4 and 10 weeks post-
PDT (Allison et al., 2004; Castano et al., 2004; Detty et al., 2004). Despite 
these disadvantages, Photofrin® continues to be used in clinics worldwide to 
treat several cancers (Table 1.3.2) but it is not the most widely used 
photosensitiser for PDT of  skin cancers specifically (Ross et al., 2013; Wan 
& Lin, 2014). 
 
5-Aminolevunilic acid (ALA), commercially known as Levulan®, is used 
clinically worldwide (Table 1.3.2) as a topical photosensitiser for the 
treatment of superficial and nodular BCC, Bowen’s disease (a form of SCC) 
and other dermatological conditions such as actinic keratosis (Ross et al., 
2013). ALA is an endogenous photosensitizer because it is metabolized in 
the intracellular haem pathway to protoporphyrin IX which is the photoactive 
molecule that induces 1O2 production upon light activation (Calzavara-Pinton 
et al., 2007). Despite its efficacy as a topical photoensitizer, ALA is a small 
lipophilic molecule and therefore has relatively weak penetration into skin 
tissue (Wan & Lin 2014).  
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ALA which is  methylated with an ester to form methyl-aminolevunilic acid 
(MAL; Metvix®) is clinically used in several European countries, New 
Zealand and Australia for the treatment of BCC and in situ SCC (Table 1.3.2) 
(Wan & Lin 2014). MAL has improved tissue penetration compared to ALA as 
it is slightly more hydrophobic thereby penetrating more easily across plasma 
cell membranes and entering skin cancer cells more readily (Stapleton & 
Rhodes, 2003). The drawbacks of ALA and MAL such as poor selectivity 
when administered systemically, their shallow tissue penetration and 
reported pain during light exposure in clinics encouraged further investigation 
of improved photosensitisers for PDT (Agostinis et al., 2011; Allison et al., 
2004; Calzavara-Pinton et al., 2007; Castano et al., 2004; Detty et al., 2004; 
Ross et al., 2013; Wan & Lin, 2014).  
 
Currently, several novel photosensitizers are being tested in clinics around 
the world (Table 1.3.2). These include chlorins, bacteriochlorins, 
benzoporphyrin derivatives, pthalocyanines and porphycenes (Agostinis et 
al., 2011; Mojzisova et al., 2007). These photosensitizers  have been named 
second generation photosensitizers due to less reported skin photosensitivity 
and their activation by longer wavelengths of light (>600nm) (Calzavara-
Pinton et al., 2007; Mojzisova et al., 2007). Although both of these are 
desirable characteristics, shorter wavelengths of light comprise higher energy 
(Alexiades-Armenakas, 2006; Karrer, Szeimies, Hohenleutner, & Landthaler, 
2001; Mang, 2004). Therefore, the combination of light penetration depth and 
light energy must produce sufficient 1O2 to cause cytotoxicity (Castano et al., 
2004). In order to improve photosensitizer uptake and intracellular 
localization, photosensitizers are often coupled to carrier molecules such as: 
antibodies, peptides, nanoparticles or are encapsulated in lipids or other bio 
materials. (Agostinis et al., 2011; Konan, Gurny, & Allémann, 2002; 
Vandongen, Visser, & Vrouenraets, 2004). 
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Table 1.3.2 Photosensitizers Currently Used During Clinical PDT (Agostinis et 
al., 2011) 
 
 
 
 
1.3.3. PDT Efficacy and Outcome: Light Source Activation 
Once the photosensitiser has been internalized by cancer cells, the tumor 
lesion is irradiated with an appropriate light source that should ideally 
correspond to the peak absorption peak of the photosensitiser (Robertson et 
al., 2009). Various light sources may be used for photosensitiser activation 
during PDT including laser light, UV lamps, white light, light emitting diodes 
(LEDs), short arc plasma discharge lamps, xenon lamps and more recently, 
sunlight (Alexiades-Armenakas, 2006; Calzavara- Pinton, 2007; Mang, 2004; 
Ross et al., 2013). 
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Lasers, the most common light source used during PDT (Ross et al., 2013; 
Wan & Lin, 2014) exist as several different types - diode lasers emitting 
continuous wave light (red, green or blue) or intense pulsed light, potassium 
titanyl phosphate lasers, pulse dye lasers, infrared lasers, CO2 lasers, argon 
lasers and Nd:YAG lasers (Karrer et al., 2001; Mang, 2004; Ross et al., 
2013; Wan & Lin, 2014). Diode lasers are the most popular because they are 
small, cost effective and have automated dosimetry and calibration rendering 
them practical and relatively easy to use by the clinician (Alexiades-
Armenakas, 2006; Karrer et al., 2001; Mang, 2004). Moreover, lasers can be 
attached to one or several flexible fiber optic cables and endoscopes that 
allow for the irradiation of interstitial tissues, internal organs and tumors 
(Alexiades-Armenakas, 2006; Mang, 2004). 
 
PDT efficacy is dependent on the light dose which is measured by two key 
parameters: fluence of the light beam and the fluence rate (Hamblin & 
Huang, 2013; Splinter & Hooper, 2007; Vo-Dinh, 2003). The first important 
parameter fluence (J/m2), is the amount of light energy that reaches a unit of 
area, taking into account that some of the energy is lost due to light by 
diffusion and scattering when it penetrates tissue (Hamblin & Huang, 2013; 
Splinter & Hooper, 2007; Vo-Dinh, 2003). The second important parameter in 
light delivery is the fluence rate (W/cm2), defined as the power (light energy 
per unit of time) that is delivered taking into account that energy is dissipated 
by diffusion and scattering upon tissue penetration (Hamblin & Huang, 2013; 
Splinter & Hooper, 2007; Vo-Dinh, 2003). The fluence and power of the light 
beam emitted by diode lasers can be adjusted manually or automatically 
which allows for improved light dosimetry during PDT and enables the 
user/laser to calculate accurate irradiating time (Splinter & Hooper, 2007). 
 
Characteristics of an ideal light source include  maximal absorption by a 
photosensitizer, good tissue penetration, a high fluence rate to generate 1O2 
in minimal irradiating time, precise targeting of tumour tissue and minimal 
skin photosensitivity and discomfort (Alexiades-Armenakas, 2006). Although 
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there is currently no ideal photosensitizer and its complementary light source 
for PDT of skin cancers; up and coming PDT research is aiming to address 
this, by investigating novel photosensitisers and their possible light sources 
for the treatment of skin cancers, especially melanoma skin cancer (Ross et 
al. 2013; Wan & Lin 2014).  
 
 
1.4. The Photochemical and Photophysical Properties of 
Hypericin 
Hypericin (HYP) is a deep red pigment primarily found in the leaves and 
flowers of the plant Hypericum perforatum L. commonly known St John’s 
Wort (Figure 1.4.1 A) which can be extracted from this plant using high 
performance liquid chromatography (Krammer & Verwanger, 2012; A. L. 
Miller, 1998; Zobayed, Afreen, Goto, & Kozai, 2006). Although HYP is a 
natural photosensitiser, it can also be chemically synthesized using 
successive oxidations of its precursor emodin anthraquione to yield 
protohypericin, which upon light exposure, is converted to hypericin (Karioti & 
Bilia, 2010; Van de Putte, Roskams, Vandenheede, Agostinis, & de Witte, 
2005; Zobayed et al., 2006). HYP is a  lipophilic, polycyclic, aromatic 
naphthodianthrone (Figure 1.4.1 B) that is stable in solution and at room 
temperature and can be stored at -20°C in the dark (Karioti & Bilia, 2010; 
Van de Putte et al., 2005). 
 
The photophysics of HYP include optimum light absorption at 560-595nm 
(green-orange visible light spectrum) (Figure 1.4.1 C) and red fluorescence 
emission at 600-640nm in organic solvents (Kiesslich, Krammer, & Plaetzer, 
2006; Theodossiou, Hothersall, Witte, Pantos, & Agostinis, 2009). According 
to laser spectroscopy analyses, HYP is a potent natural promising 
photosensitiser because it has strong electron donating potential in polar 
solvents and therefore has a high quantum yield that results in  generous 1O2 
production upon light activation (Theodossiou et al., 2009). Therefore,  
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hypericin induced PDT (HYP-PDT) can initiate potent cytotoxic 
consequences in cancer cells but this is primarily dependent on the 
localization of HYP upon light activation and to a lesser extent  the dose of 
HYP, the uptake/incubation time of HYP and the light dose used to activate 
HYP (Agostinis, Vantieghem, Merlevede, & de Witte, 2002). 
 
High tumour selectivity in vivo is also another important characteristic of 
HYP, for example in mice, HYP accumulation in subcutaneous tumor tissue 
was 16 fold higher in concentration than normal skin and muscle surrounding 
tissue after intravenous administration of HYP (5mg/kg) (Chen & de Witte, 
2000).  
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A) 
 
Adapted from (Karioti & Bilia, 2010) 
B) 
 
Adapted from (Nahrstedt & 
Butterweck, 2010) 
C) 
 
Figure 1.4.1: Hypericum perforatum L. (St John’s Wort) (A); HYP chemical 
structure (B) and HYP absorption spectrum with the peak absorption peak at 
563nm (C) 
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1.5. Hypericin Uptake and Localization 
HYP is a monobasic salt in physiological solutions and due to its 
hydrophobicity it forms aggregates in physiological aqueous environments 
(Agostinis et al., 2002; Krammer & Verwanger, 2012). This allows HYP to 
bind readily to low density lipoproteins (LDL); high density lipoproteins (HDL) 
and serum albumin in the blood and can therefore be transported 
systemically around the body (Lavie, Mazur, Lavie, & Meruelo, 1995). HYP 
solubility can be improved by conjugating it to biomolecules such as 
polyvinylpyrrolidone (PVP) for improved transport and delivery to the tumor 
tissue (Kubin et al., 2008). 
 
Once the HYP and LDL/HDL complexes reach the interstitial tissue, HYP can 
be taken up by LDL/HDL receptor mediated endocytosis or via passive 
diffusion after dissociation from the LDL/HDL molecules; because the 
hydrophobic moieties of HYP can interact with cholesterol molecules of the 
hydrophobic regions in plasma cell membranes allowing for easy breaching 
across the plasma membrane  (Jori & Reddi, 1993; Karioti & Bilia, 2010; 
Siboni et al., 2002; Van de Putte et al., 2005). Furthermore, HYP can also 
interact with micromolecules in the tumor microenvironment such as collagen 
and can penetrate through the tumor microenvironment ECM,  possibly 
because of  the decrease in E-cadherin and loss of intracellular adhesion in 
tumor tissue (Krammer & Verwanger, 2012; Van de Putte et al., 2005).  
 
In vivo, HYP is preferentially taken up by cancer cells because cancer cells 
have more LDL/HDL extracellular receptors compared to normal cells 
however, this is not the case in vitro as HYP is taken up readily by both 
normal and cancer cells via passive diffusion (Kamuhabwa, Agostinis, 
D’Hallewin, Kasran, & de Witte, 2000; Siboni et al., 2002). The rate of HYP 
uptake can vary depending on the dose and cell type; although the current 
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recommended uptake time for HYP in vitro is 2- 4 hours (Agostinis et al., 
2002; Kiesslich et al., 2006; Theodossiou et al., 2009).  
 
Once HYP is inside a cell, it preferentially localizes to organelle membranes 
and has been reported to localize in the membranes of the ER, mitochondria, 
Golgi apparatus, lysosomes and melanosomes but this localization which 
seems to be correlative with uptake, is cell type and dose-dependent 
(Agostinis et al., 2002; L M Davids & Kleemann, 2010; Kleemann, Loos, 
Lang, Scriba, & Davids, 2014; Krammer & Verwanger, 2012; Skalkos et al., 
2006; Theodossiou et al., 2009). Furthermore, HYP localization in the 
nucleus although rare, has been reported after prolonged periods of time and 
at very high doses (>20µM) (Krammer & Verwanger, 2012).  
 
 
1.6. Cytotoxic Effects of Hypericin-Induced Photodynamic 
Therapy 
Activated HYP generates ROS in the vicinity of its localization because 1O2 
has a  very short half-life (<0.04µs), and can diffuse a distance of 
approximately 20nm (Davies, 2003; Moan & Berg, 1991). This infers that 
hypericin-induced photodynamic therapy (HYP-PDT) ROS induced cell 
damage, occurs mostly in cell and organelle membranes in the form of 
protein and/or lipid peroxidation (Agostinis et al., 2002; Davies, 2003; 
Krammer & Verwanger, 2012; Moan & Berg, 1991). Subsequently, HYP-PDT 
can  lead to different forms of cell death such as apoptosis or necrosis or 
may induce cell survival via autophagy, although autophagy has recently 
been deemed a cell death mechanism (Agostinis et al., 2002; Mikeš, 
Jendželovský, & Fedoročko, 2013; Ouyang et al., 2012; Shen, Kepp, & 
Kroemer, 2012; Theodossiou et al., 2009).  
 
Briefly, apoptosis results in cell shrinkage, chromatin condensation, DNA 
fragmentation and membrane blebbing preceding the formation of apoptotic 
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bodies, (membrane enclosed vesicles containing cellular debris) which are 
efficiently phagocytozed by neighboring cells; thereby avoiding an 
immunogenic response (Fiers, Beyaert, Declercq, & Vandenabeele, 1999; 
Kerr, Wyllie, & Currie, 1972). In contrast, necrosis induces a powerful 
immune response because of cellular content spillage  once the cell 
cytoplasm and organelles swell and the plasma membrane has burst (Fiers 
et al., 1999). Autophagy ensures recycling of damaged organelles by means 
of enzymatic degradation in membrane bound autophagasomes that become 
fused with lysosomes containing hydrolases (Levine & Klionsky, 2004). 
However, persistent autophagy can instigate cell death as essential 
organelles get degraded cell metabolism and integrity is compromised; which 
can lead to apoptosis (Marino, Niiso-Santo, Baechrecke, & Guido, 2014; 
Rubio et al., 2012; Shen et al., 2012). 
 
 
1.7. HYP-PDT Induced Apoptosis 
Apoptosis is regulated by complex intracellular pathways (Figure 1.7.1)  
(Marino et al., 2014; Ouyang et al., 2012; Vandenabeele, Galluzzi, Vanden 
Berghe, & Kroemer, 2010). Briefly, the key mediators of apoptosis are the 
cytoplasmic caspases (9; 8; 3; 5; 7) (Figure 1.7.1), which are proteolyticly 
cleaved in a cascade fashion that induces translocation of poly (ADP-ribose) 
polymerase PARP into the cell nucleus which is then able to cleave DNA into 
fragments (Hengartner, 2000). The caspase cascade can be activated by 
either the intrinsic  or the extrinsic apoptotic pathway (Ouyang et al., 2012).  
 
The extrinsic pathway (Figure 1.7.1) is initiated by the binding of death ligand 
to their death receptors such as: tumor necrosis factor α (TNF α); tumor 
necrosis factor-related apoptosis inducing ligand (TRAIL) and Fas ligand 
(FASL)  at the cell membrane which leads to receptors clustering and 
associating with adaptor proteins such as Fas associated death domain 
protein (FADD);  leading to caspase activation (Ashkenazi & Dixit, 1999). The 
intrinsic apoptosis pathway (Figure 1.7.1) involves mitochondrial membrane 
35 
 
compromise after an insult and subsequently releasing cytochrome C (Cyt C) 
into the cytosol through a “leaky” mitochondrial membrane (Green & 
Walczak, 2013; Hengartner, 2000). Cyt C release is induced by key apoptotic 
proteins: B cell lymphoma 2 (Bcl 2); BAK and Bid and it allows Cyt C to form 
complexes with other apoptotic proteins to activate the caspase cascade 
(Fadeel, Zhivotosky, & Orrenius, 1999; Green & Walczak, 2013).  
 
If HYP localizes in the mitochondrial membrane, HYP-PDT down regulates 
matrix metalloprotease 1; inhibits protein kinases such as PKC and impairs 
mitochondrial function thereby inducing apoptosis (Agostinis et al., 2002). 
HYP- PDT has been shown to activate the intrinsic apoptotic pathway by up 
regulating Bcl2; inhibiting mitochondrial membrane hexokinase,  inducing Cyt 
C release, activating the caspase cascade; and causing DNA fragmentation 
(Agostinis et al., 2002; Karioti & Bilia, 2010; Kiesslich et al., 2006; 
Theodossiou et al., 2009). The extrinsic apoptotic pathway involving 
cathepsin D release and the lysosomal pathways has also been reported due 
to HYP-PDT (Agostinis et al., 2002; Kiesslich et al., 2006; Theodossiou et al., 
2009).  
 
Furthermore, should activated HYP reside in the ER, 1O2 can damage the 
sarco/endoplasmic Ca2+ ATPase 2 (SERCA 2) pump which causes release 
of Ca2+ from ER Ca2+ stores into the cytosol (Buytaert et al., 2006).  Ca2+ can 
act as a 2nd messenger molecule in the cytosol and activate PKC and the 
pro-apoptotic protein BAK, which stimulates the extrinsic apoptotic cascade 
via mitochondrial membrane permealization and Cyt C release (Agostinis et 
al., 2002; Buytaert et al., 2006). Furthermore, HYP-PDT treated cells may 
also send “eat me” signals via damage associated molecular patterns 
(DAMPs) such as heat shock protein 70 (HSP 70) and calreticulin which are 
externalized and can induce an immunogenic response to ensure 
opsonization of dead cells and possibly infer anti-tumor immunity (Garg & 
Agostinis, 2014; Garg et al., 2013). 
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Figure 1.7.1: The mechanism of apoptosis (Adapted from Marino et al. 2014) 
 
 
1.8. HYP-PDT and Prosurvival Effects 
Some of the pro-survival mechanisms which have been associated with 
HYP-PDT include up regulation of: JNK 1,  MAPKs;  PIP 3; ERK 2; 
ceramides, cyclin dependent kinases and some second messenger 
molecules (Assefa et al., 1999; Oleinick & Evans, 2010). Furthermore, an 
increase in the activity of antioxidants such as  superoxide dismutase (SOD) 
and glutathione have also been observed immediately post HYP-PDT which 
may contribute to cancer cell resistance to HYP-PDT (Agostinis et al., 2002; 
Karioti & Bilia, 2010; Kiesslich et al., 2006; Kubin, Wierrani, Burner, Ualth, & 
Grünberger, 2005; Theodossiou et al., 2009). It is important to note that the 
cellular response to HYP-PDT is dependent on a number of factors: the cell 
type; the dose of HYP; the dose of light and most importantly where inside 
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the cell the HYP is residing when it gets activated by light and produces ROS 
(Agostinis et al., 2002; L M Davids & Kleemann, 2010; Theodossiou et al., 
2009). 
 
 
1.9. HYP-PDT and In Vitro Skin Cancer Studies 
We, and others have investigated the cytotoxic effects induced by HYP-PDT 
in human skin cancer cells (Davids et al. 2008; Davids et al. 2009; Sanovic et 
al. 2009; Blank et al. 2003; Sharma & Davids 2012; Gyenge et al. 2013; 
Hadjur et al. 1996; Sharma et al. 2011).  
 
A study by Sanovic et al. 2009, conducted gene profiling using gene 
microarray analysis of apoptotic genes in A431 SCC cells at 1.5; 3; 5 and 6 
hours post HYP – PDT. Upregulation of pro-survival  proteins p38MAPK JNK, 
ERK and RAS were observed when cells were treated with HYP, only (in the 
dark) or low concentrations (< 3µM) of HYP-PDT (Sanovic et al., 2009). 
However, they also reported on possible indications of apoptosis genes being 
upregulated such as ERK and RAS and perinuclear localization of HYP; 
when cells were treated with a higher dose (200ng/ml) of HYP-PDT; 
incorporating a longer HYP uptake time (16hrs) (Sanovic et al., 2009). 
Another study that used a different SCC cell line (SQ2) showed that these 
cells experienced a G2-M cell cycle arrest as a result of heat shock protein 
90 and 70 ubiquitination, after treatment with HYP in the dark (Blank et al., 
2003). 
 
Our group reported on a novel “double hit/day strategy” approach by treating 
human SCC cells with multiple, consecutive HYP-PDT doses,  which resulted 
in rapid necrotic cell death (Sharma & Davids, 2012). In corroboration, 
Gyenge et al. 2012, recently reported a 30%  increase in apoptosis and 
increased ROS levels in UMB-SCC745 and UMB-SCC969 (head and neck 
SCC  cells) were observed 3 hours post HYP-PDT (Gyenge et al., 2012). 
Furthermore, in a different study by the same group, 96%  cell death was 
38 
 
observed at a dose of 2.5µg/ml HYP (5hr incubation) which was activated 
with white light (Gyenge, Emina et al., 2013). Interestingly, they also showed 
that the cytotoxicity of HYP alone was higher than when cells were treated 
with a 1:1 mixture of HYP and the photosensitiser  mTHPC (Gyenge, Emina 
et al., 2013).  
 
With regards to melanoma cells, our group has investigated the effect of 
HYP-PDT and established an effective  “killing does” of 3µM HYP which was 
activated with UVA (Lester M Davids et al., 2008). Interestingly, HYP-PDT 
induced different cytotoxic responses in pigmented UCT Mel-1 and 
unpigmented UCT Mel-3 cells: UCT Mel-3 cells underwent apoptosis and 
UCT Mel-1 cells underwent necrosis with the pigmented UCT Mel-1 cells 
being less susceptible to HYP-PDT than the unpigmented UCT Mel-3 cells 
(Lester M Davids et al., 2008). This supported the hypothesis stipulated by 
Hadjur et al. 1996, that melanin present in pigmented (melanotic) melanoma 
cells may play a role in  melanoma cell response to HYP-PDT (Hadjur et al., 
1996).  
 
Furthermore, our laboratory did two follow up studies which involved 
depigmenting pigmented UCT mel1 cells with tyrosinase inhibitors (block 
melanogenesis pathway) kojic acid and phenylthiourea;  preceding HYP-PDT 
treatment that rendered the pigmented UCT Mel-1 cells more sensitive to 
HYP-PDT, similarly to unpigmented A375 melanoma cells (Sharma et al., 
2011; Sharma, Davids, & Krishna V. Sharma and Lester M.Davids, 2012). 
Lastly, using electron microscopy, our group also established that an initial 
autophagic response is induced in both unpigmented and pigmented human 
melanoma cells, 4 hours post treatment with 3µM HYP-PDT (Davids et al. 
2009). 
 
Another interesting approach used pulsed laser therapy as the light modality 
of HYP-PDT by testing different light  wavelengths (514nm – 593nm) and  
using different exposure times (5-120s) to activate a range of  HYP (0.1-
2mM) concentrations in order to suggest a LD50 dose of light and HYP for 
SNU-1 SCC cells (Bublik et al., 2006). Several different laser settings were 
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effective in activating HYP to achieve LD50 of SNU-1 cells (Bublik et al., 
2006). 
 
Further in vitro studies are needed to elucidate the cellular mechanisms 
induced by HYP-PDT in human skin cancer cells, in order to fully understand 
the mechanism of action of HYP-PDT in this system.  
 
 
1.10. HYP-PDT and In Vivo Skin Cancer Studies 
To date, few in vivo studies have been published on HYP- PDT (A Boiy, 
Roelandts, & de Witte, 2011; A Boiy, Roelandts, van den Oord, & de Witte, 
2008; Annelies Boiy, Roelandts, & de Witte, 2007; Head, Luu, Sercarz, & 
Saxton, 2006). One group tested a range of HYP does (0.1- 10µg/ml) and 
different wavelengths of light on SNU 1 (SCC) cells before intralesionally 
injecting these cells into nude mice and allowing the tumors to grow over a 
period of 6-8 weeks (Head et al., 2006). HYP-PDT resulted in regression of 
tumors which were originally smaller than 0.4cm2 but PDT was ineffective in 
the treatment of larger tumors  (Head et al., 2006). Another group 
investigated topical application of 0.1% HYP on mice skin and suggested that 
24 hours is needed for homogenous HYP distribution in UVR induced skin 
tumors in mice and that HYP tissue penetration can be improved using lipid 
carriers and esterification of HYP (A Boiy et al., 2008; Annelies Boiy et al., 
2007). 
 
Two clinical studies have been carried out investigating HYP-PDT  and non-
melanoma skin cancer (Alecu et al., 1998; Kacerovská, Pizinger, Majer, & 
Smíd, 2008). Alecu et al, 1998, stipulated that HYP-PDT targeted tumors 
selectively as no necrosis or tissue damage was observed in surrounding 
tissue but the effectiveness of HYP-PDT was dose dependent with higher 
doses almost completely eradicating tumors  with a favorable cosmetic 
outcome (Alecu et al., 1998). This study included 8 SCC and 11 BCC 
patients and HYP was administered intralesionaly to SCC patients (40-
100mg) 3-5 times during 2-4 weeks and to BCC patients (40-200mg) 3-5 
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times during 2-6 weeks therefore, not only the dose of HYP but also the 
frequency and duration of HYP-PDT affected the outcome (Alecu et al., 
1998). However, another treatment protocol was used by Kacerovska et al. 
2008, to treat 8 actinic keratosis patients, 21 BCC patients and 5 Bowmen’s 
disease (SCC) patients: HYP (2mg/ml)  was administered topically (10mm 
thick onto lesion) for 2 hours and activated with red light (75 J/cm2); which 
was carried out once each week, for 6 weeks (Kacerovská et al., 2008). 
Promising results suggested that 50% of actinic keratosis patients; 28 % of 
BCC patients and 40% of Bowman’s disease patients had successful 
outcome post HYP-PDT with the histological analysis showing complete 
eradication of 11% of the BCC and 40% of the bowmen’s disease lesions 
(Kacerovská et al., 2008).  
 
The discrepancies between treatment protocols in these two studies are 
evident as there is currently no standardized regime for clinical HYP-PDT for 
the treatment of skin cancers. Furthermore, in vivo PDT is influenced by 
several factors such as the method of HYP administration, the irradiation 
protocol, the type of tumor and the oxygenation levels in the tumor (Agostinis 
et al., 2011, 2002). However, both studies showed some promising results 
that support HYP-PDT as a potential treatment option for NMSC despite 
more clinical trials with increased patient sample sizes, being required. To 
our knowledge, no clinical trials have been conducted to investigate HYP-
PDT for the treatment of melanoma.  
 
 
1.11. The Bystander Effect of HYP-PDT on Normal Cells  
A bystander effect, defined as indirect damaged induced into adjacent cells 
either via intercellular gap junctions or via diffusible ROS released in the 
microenvironment, has been shown to occur during PDT (Dahle, Kaalhus, 
Moan, & Steen, 1997; Dahle, 2000). It is well know that cancer therapies 
have bystander effects on normal cells in the body which often cause 
undesirable side effects (De Angelis, 2008; Ehmann, Heinemann, & 
Wollenberg, 2011; Langer et al., 1989). As PDT has been shown to be 
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effective through topical administration to treat skin cancers, it is important to 
know what its effect, if any, is on the normal cells population surrounding the 
NMSC or Melanoma.  
 
Till now, very few studies have investigated the effect of HYP-PDT on normal 
skin cells. To our knowledge, us and a few other in vitro studies have been 
the only groups that have investigated the effect of HYP-PDT on normal 
human skin cells (Bernd et al., 1999; Lester M Davids et al., 2008; Hadjur, 
Richard, Parat, Favier, & Jardon, 1995; Kashef, Borghei, & Djavid, 2013; 
Rezusta et al., 2012; Traynor et al., 2005). However, most of these studies 
used immortalized cell lines such as the HaCaT immortalized keratinocyte 
cell line (Bernd et al., 1999; Lester M Davids et al., 2008; Rezusta et al., 
2012); MRC5 immortalized fibroblast cell line (Hadjur et al., 1995) and 
Hermes 4 immortalized melanocyte cell line (Lester M Davids et al., 2008). 
Furthermore, 2 of these studies investigated the effects of HYP-PDT on 
primary human fibroblasts (Kashef et al., 2013; Rezusta et al., 2012) but 
these concentrated on the effect of HYP-PDT as an antimicrobial agent.  
 
The novelty of this study is therefore the in vitro investigation into the effects 
of HYP-PDT on normal human skin cells representing both the epidermal 
(melanocytes and keratinocytes) and dermal (fibroblasts) components of the 
skin. These in turn, provide insight into the reaction of these potential cells in 
the tumor microenvironment.   
 
 
1.12. Aims 
1) To optimize tissue culture of primary human keratinocyte (Kc), 
melanocytes (Mc), and fibroblasts (Fb) from neonatal foreskins. 
2) To determine the effects of HYP-PDT on the cell viability of primary 
human skin cells. 
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3) To evaluate intracellular ROS production post HYP-PDT in primary 
human skin cells. 
4) To assess the effects of HYP-PDT on cell morphology of primary human 
skin cells. 
5) To analyze apoptosis in primary human skin cells post HYP-PDT.  
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Chapter 2: Materials and Methods 
2.1. In Vitro Human Skin Cell Culture Model 
2.1.1. Isolation of Primary Human Skin Cells 
Primary human skin cells were isolated from human neonatal, adult foreskins 
and human tissue obtained from plastic and reconstructive surgeries via full 
consent and approval by our institutional board (REC REF 493/2009). Briefly, 
skin tissue was collected in Dulbecco’s Modified Eagles Medium (DMEM) 
(Highveld Biological, South Africa; Appendix A) supplemented with antibiotics 
(100 U/ml penicillin / 100µg/ml streptomycin; Appendix A) (Sigma- Aldrich: 
P3032/S91370) and stored at 4ºC. Skin tissue was cut into smaller pieces 
(5mm X 2.5mm) and sub-merged in 5mg/ml of dispase solution (Sigma- 
Aldrich: D4693) overnight at 4ºC. The epidermis was then separated from the 
dermis according to standard protocols (Appendix A).  
 
Primary human melanocytes (Mc) and keratinocytes (Kc) were further 
isolated from the epidermis by incubating the smaller epidermal samples  in 
trypsin  supplemented with 0.1% glucose (Appendix A) in a 37ºC water bath 
for 15 minutes. This suspension was triturated every 5 minutes to 
disaggregate the tissue into a cellular suspension. The suspension was then 
filtered through a 70µm Whatman filter (BD BioSciences, USA). To exclude 
tissue debris, the cell suspension was pelleted at 3000 rpm for 5 minutes at 
room temperature. The pellet was then resuspended in complete cell-specific 
(Mc or Kc) media (section 2.1.2); depending on whether Mc or Kc were the 
desired cell type.  The settled cells were denoted passage 0 and fresh 
specific complete medium was added to the cells once they had adhered 
overnight. 
 
Primary human fibroblasts (Fb) were isolated from dermal samples by 
placing the whole tissue piece underneath a glass coverslip (Marienfeld 
Laboratory Glassware, Germany) in a 35mm tissue culture dish (Greiner Bio-
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one, Germany); containing complete cell-specific medium (section 2.1.2). 
Thereafter, Fb   spontaneously migrated away from the fixed tissue onto the 
tissue culture dish. After 10 days, the glass coverslip was removed and the 
settled Fb were denoted as passage 0.  Mc, Kc and Fb were cultured for 2-3 
weeks to obtain pure cell populations.  
 
 
2.1.2. Tissue Culture Conditions 
Fb, Mc and Kc were cultured in different cell specific complete media in a 
tissue culture incubator (MCO-175M, Sanyo, United Scientific, South Africa) 
at 37 ºC in a humidified atmosphere with 5% CO2. Fb were cultured in DMEM 
(Highveld Biological, South Africa) (Appendix A) supplemented with 10% 
(v/v) heat inactivated fetal bovine serum (FCS) (Highveld Biological; 
Appendix A) and antibiotics (100 U/ml penicillin / 100µg/ml streptomycin; 
Appendix A) (Sigma- Aldrich: P3032/S91370). Mc were cultured in Mc 
specific medium (FETI) (Appendix A). Kc were cultured in Kc specific 
medium (KSFM) (Gibco®, Life technologies, United Kingdom) supplemented 
with: 25mg bovine pituitary extract (BPE); 2.5µg epidermal growth factor 
(EGF) and antibiotics (Appendix A) (Gibco®, Life Technologies: 17005034; 
130 28-014; 10450 013, United Kingdom). However, when Kc were cultured 
for periods exceeding passage 3 and during experiments, they were 
maintained in a different Kc-specific medium called GREENS (Appendix A).  
 
Trypsin/EDTA (Appendix A) was used to lift adherent Fb and Mc whereas 
commercial TrypLE™ Express (Gibco®, Life Technologies, United Kingdom) 
or commercial trypsin/EDTA (Gibco®, Life Technologies, United Kingdom) 
were used to lift adherent Kc from tissue culture dishes. Additionally, FCS 
(included in complete medium) was used as a trypsin inhibitor, when lifting 
cells from tissue culture dishes. Cultured primary human skin cells used in all 
experiments did not exceed passage 12 and cells were viewed frequently 
under a bright field microscope (Olympus Microscope Model CK2, Olympus 
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Microscopes). Routine weekly mycoplasma tests were employed with 
Hoechst nuclear dye (Appendix A) to maintain sterility in all cultures. Cells 
were often pooled from different dishes and patients in order to obtain 
enough cells for an experiment (one biological repeat). 
 
 
2.1.3. Growth Curves 
Growth curves were conducted over a period of 7 days using: Fb, Mc and Kc 
to establish the seeding efficiency of these cells and to investigate their 
growth dynamics. Fifty thousand (5x104) Fb and Mc and 1.5x105 Kc were 
seeded in triplicate in 35mm cell culture dishes (Greiner-Bio One, Germany) 
in cell-specific complete medium. The day on which cells were seeded was 
designated as day 0 and Mc were counted manually on days: 1, 3, 5 and 7 
and Kc were counted on days: 2; 3; 5 and 7 using a haemocytometer 
(Neubauer improved, Marienfeld Laboratory Glassware, Germany). This 
experiment included 3 technical repeats, within each biological repeat and 
included 3 biological repeats (n=3).  
 
 
2.2. Photodynamic Therapy (PDT) 
2.2.1. Hypericin Preparation 
Hypericin (HYP) extract from the species Hypericum perforatum L. (Sigma- 
Aldrich: 56690, 99% purity) was prepared in 1ml of 100% dimethyl sulfoxide 
(DMSO) (Merck: 8.02912.1000) to obtain a 2mM stock solution (Appendix A), 
which was further stored in 20µl aliquots at –80ºC. A 20µM working stock 
was freshly prepared in phosphate-buffered saline (1xPBS) which was further 
diluted in complete media to attain the required concentrations during all PDT 
experiments.  All experiments involving HYP were carried out under subdued 
light conditions due to the light-sensitivity of HYP.  
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2.2.2. Laser Light Activation  
HYP was activated with a yellow/green light emitted from a diode pumped, 
solid state, continuous wave, tunable laser that emits a light beam of exactly 
561nm; which is delivered via a fibre optic cable. This laser was obtained via 
a grant from the National Laser Centre at the Centre for Scientific and 
Industrial Research (NLC-LREHGOO-CON-001). The power and fluence of 
the light dose were kept constant at 20mW and 5J/cm2 respectively, for all 
experiments involving laser light to activate hypericin. The irradiation time 
was calculated using the following equation: 
 
 
Equation 2.1: Laser Irradiation Time 
Time (s) = Fluence (J/cm2) / Power density= (W/cm2) 
*power density = fluence rate (W/cm2) 
 
 
The irradiation time used in our experimental set up was dependent on the 
area of the bottom of the well or dish which was being irradiated (Table: 
2.21). The size of the laser-light beam was adjusted, using the aperture 
connected to the light-emitting fibre optic cable, to the exact area of the 
bottom of the well or dish used in different experiments. Therefore, light 
refraction from the sides of the well or dish did not need to be accounted for 
when calculating the light dose. Dark (unirradiated) controls were covered 
with foil at all times and were not exposed to the laser light.   
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Table 2.2.1: Laser parameters Used to Calculate Irradiating Time of Tissue 
Culture Dishes during HYP-PDT Treatment Protocol 
Dish/
well 
size 
Diameter 
(cm) 
Area 
(cm2) 
Fluence 
(J/cm2) 
Power 
(W) 
Fluence 
rate/power 
density 
(W/cm2) 
Calculation 
using 
equation 1 
Irradiation 
time 
 
1well 
/96 
well 
plate 
0.5 0.196 5 0.02 0.02/ 0.196 5/ 
(0.02/0.196) 
49s 
35mm 
dish 
3.5 9.621 5 0.02 0.02/9.621 5/ 
(0.02/9.621) 
 
2405s  
= 40mins 
1 well 
/24 
well 
plate 
1.5 1.767 5 0.02 0.02/1.767 5/ 
(0.021/1.767) 
421s   
=7mins 
 
 
2.2.3. Hypericin Induced Photodynamic Therapy (HYP-PDT) 
HYP-PDT involved treating primary human skin cells with hypericin (HYP) 
and laser light. Briefly, cells were incubated for 4 hours at 37ºC in a 5% CO2 
humidified tissue culture incubator (MCO-175M, Sanyo. United Scientific, 
South Africa) with various doses of HYP (0.5µM - 4 µM), in cell-specific 
complete media (Appendix A). Following the incubation period, cells were 
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rinsed twice with 1xPBS (Appendix A) and irradiated in 1xPBS.  Irradiation 
time was dependent on the size of the well or dish (Table 2.2.1).  
 
The following controls were included in all experiments: 
 Untreated control: cells were not treated with HYP or light (C) 
 Vehicle dark control: cells treated with 0.15% DMSO only (VC) 
 Dark HYP controls: cells treated with HYP only (H) 
 Light only control: cells treated with light only (L) 
 Vehicle light control: cells treated with 0.15% DMSO and light (VL) 
 HYP-PDT: cells treated with HYP and activated with light  (H+L) 
 
Post-irradiation, the wells were replenished with fresh medium. As HYP is 
sensitive to auto-oxidation, all experiments involving HYP-PDT were: carried 
out in subdued light conditions, all dark and untreated controls were plated in 
a separate unirradiated plate or dish and plates/dishes were covered with foil 
at all times. 
 
2.3. Cell Viability Assay 
Cell viability of Fb, Mc and Kc was assessed 24 hours post-HYP-PDT 
treatment; using the XTT metabolic-based viability assay (Cell proliferation kit 
II (XTT); Roche: 11465015001). Briefly, the cells were seeded in triplicate in 
2 separate 96 well plates (TRP®, Switzerland: 92096) in 200µl of cell specific 
complete media. In order to obtain 80% confluency, 2x104 Fb and 7x104 Mc 
and Kc were seeded per well and allowed to adhere overnight. The following 
day, cells were treated with a range of HYP doses (0.5µM; 1µM; 2µM; 3µM; 
4µM) as described in (section 2.2). Twenty four hours (24hrs) post HYP-PDT 
treatment, cell viability was assessed. The basis of the cell viability assay is 
the cleavage of the XTT tetrazolium salt by mitochondrial dehyrogenases to 
yield an orange formazan product. Thus, only metabolically active cells will 
induce a colorimetric change that is detected at an absorbance of 450nm. 
Following the kit’s protocol, the final reading was done using an ELSIA plate 
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reader (VERSAmaxTM tunable microplate reader, Molecular Devices). In 
order to account for technical or pipetting error within an experiment, 3 
technical repeats were included in each biological repeat. This experiment 
comprised 3 biological repeats (n=3). 
 
 
2.4. Reactive Oxygen Species (ROS) Assay 
A fluorescent-based ROS assay was used to detect intracellular ROS 
immediately after HYP-PDT treatment. This assay involved exposing the 
cells to the cell permeable non-fluorescent probe 2’, 7’– dichlorofluorescein 
diacetate (DCF-DA), which upon oxidation by intracellular esterases in the 
presence of intracellular ROS, is cleaved to yield the fluorescent product 
dichlorofluorescein (DCF). Intracellular ROS is therefore indirectly measured 
by intracellular DCF fluorescence. Twenty thousand Fb (2x104) and 7x104 Mc 
and Kc were seeded per well, in triplicate, in 200µl of cell specific complete 
medium, in 2 separate 96 well white plates (Greiner Bio- One: 655083, 
Germany). Once the cells had adhered overnight, Fb and Mc were both 
treated with 1µM and 3µM HYP- PDT and Kc were treated with 3µM and 
4µM HYP- PDT according to the protocol described in section 2.2.  
 
Immediately after HYP-PDT, 5µM of DCF-DA (Sigma-Aldrich: 35845) 
(Appendix A), prepared in cell specific complete medium, was added to each 
well (100µl). Following a 20 minute incubation at 37ºC, the DCF- DA 
containing medium was removed and the cells were washed twice with 100µl 
of 1xPBS (Appendix A) and fresh 1xPBS (100µl) was added to each well. 
The fluorescence was then measured using a fluorimeter (Cary Eclipse 
e104043731) at an excitation wavelength of 488nm and an emission 
wavelength of 535nm. The blank reading (1xPBS only) was deducted from 
each recorded value preceding data analysis. This experiment was 
conducted under subdued light conditions (section 2.2) and every biological 
repeat included 3 technical repeats. However,  there were 3 biological 
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repeats for the Fb (n=3) and Kc (n=3) but 4 biological repeats were 
conducted using the Mc (n=4).   
 
 
2.5. Cell Morphology Analysis 
Cellular morphology of Fb, Mc and Kc was assessed 24 hours post HYP-
PDT with phase and fluorescent microscopy. One hundred thousand (1x105)  
Fb and Mc and 1.5x105 Kc were seeded directly onto glass coverslips 
(Marienfeld Laboratory Glassware, Germany) in 35mm tissue culture dishes 
(Greiner Bio- One, Germany) in 400µl of complete cell specific medium. Cells 
adhered to the glass coverslip in a drop of medium through surface tension 
overnight. Complete cell specific medium (1.6ml) was added to each 35mmm 
dish on the following day. Cells were then cultured from 2-7 days according 
to tissue culture conditions described in section 2.1.1, in order to achieve 
80% confluency on the glass coverslips (Marienfeld, Germany). Cells were 
then subjected to HYP- PDT treatment using a dose of 1µM and 3µM HYP 
according to the protocol described in (section 2.2).  
 
Twenty four hours post HYP-PDT treatment, 1µg/ml of Hoechst Live 33342 
(Invitrogen, Molecular Probes: H1399) nuclear dye was added directly to the 
recovery medium for 20 minutes. After washing twice with 1xPBS (Appendix 
A) the cells were fixed with 4% paraformaldehyde (PFA) (Appendix A) for 20 
minutes and mounted on glass slides (Marienfeld, Germany) with 50µl of 
mowiol (Appendix A) containing an anti-fade compound (N-propyl gallate) 
(Sigma- Aldrich, 204-498-2). Phase contrast images and their 
complementary multi-acquisition fluorescent images were acquired using the 
Zeis Axiovert 200M inverted fluorescent microscope (20X and 40X 
objectives). 
 
The DAPI channel was used to view Hoechst Live, blue nuclear stain and the 
Cy3 channel to view HYP; as HYP has an inherent red fluorescence. The 
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camera exposure time was set according to the HYP- PDT treated cells 
viewed in the Cy3 channel because HYP yields an even brighter 
fluorescence upon light illumination, thereby minimizing HYP background 
fluorescence. Two biological repeats (n=2) were performed for this 
experiment using each cell type.  
 
 
2.6. Apoptosis Analysis 
Fluorescent activated cell sorting (FACS) was employed to determine early 
stage apoptosis and plasma cell membrane integrity 24 hours post HYP-PDT 
treatment. The two fluorophores that were used were Annexin V-FITC and 
propidium iodide (PI). Annexin V-FITC (green fluorophore) binds to 
phosphatidylserines, residing intracellularly on the plasma cell membrane, 
which become externalized at the onset of apoptosis. Annexin V-FITC bound 
to externalized phosphatidylserines fluoresces green and can be detected 
using FACS. PI is an intercalating agent and a red dye (red fluorophore) that 
is excluded from viable cells due to their intact plasma cell membranes. Cells 
therefore with compromised plasma cell membranes internalize the dye, 
making it a direct measure of plasma cell membrane integrity which can be 
correlated to cell viability or cell death.  
 
One hundred thousand (1x105) Fb and Mc and 1.5x105 Kc were seeded per 
well in a 24 well plate (Greiner Bio-one) in duplicate, in cell specific medium. 
Cells were cultured for 2-7 days as stipulated in (2.1.2) to achieve 80% 
confluency. Cells were then treated with 3µM HYP-PDT according to the 
protocol described in (2.2). Twenty four hours (24hrs) post HYP-PDT 
treatment, cells were processed for FACS analysis. This involved harvesting 
all cells, i.e. from the recovery medium and those adherent to the dish, with 
(trypsin/EDTA) (Appendix A) and centrifuging at 1000 rpm for 10 minutes to 
obtain cell pellets. The cells from duplicate wells were pooled in order to 
obtain sufficient cells (10 000 cells/events) per sample. The cell pellets were 
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re-suspended in 1ml of ice cold 1xPBS (Appendix A) and further centrifuged 
at 3000 rpm for 5 minutes. The pellets were then re-suspended in 300µl of 
Annexin V-FITC binding buffer (Appendix A) and placed in FACS tubes (BD 
Falcon, Biosciences, USA).  
 
Four microliters (4µl) of Annexin V-FITC working solution (BD Biosciences 
USA: 556420) and 10µl of PI (50µg/ml) (Roche, Germany) (Appendix A) 
were added directly to the cells in Annexin V binding buffer. FACS sample 
processing was carried out in subdued light conditions. The samples were 
allowed to stand at room temperature for 15 minutes before FACS was 
carried out using the FACSAria 1 cell sorting machine (BD Biosciences, 
USA). All controls discussed in section 2.2, were included in this experiment 
and fluorophores were tested by adding Annexin V-FITC and PI separately to 
HYP-PDT treated cells. FACS data was analyzed using FlowJo Software 
Version 10.0.7.0. Three technical repeats were included in each biological 
repeat. Using each cell type, 3 biological repeats were conducted during this 
experiment (n=3).  
 
Furthermore, prior to carrying out the above FACS cell death analysis 
experiment, we tested whether we could use PI in combination with HYP 
during FACS experiment because both HYP and PI are fluorophores which 
emit a red fluorescence. However, several studies had used PI when 
analyzing cell death induced by  HYP-PDT in vitro (Du, Li, Olivo, Yip, & Bay, 
2006; Huntosova et al., 2012; Kleban et al., 2006; Seitz et al., 2008). 
Therefore, Fb, Mc and Kc were treated with either HYP-PDT (no PI added) or 
stressed with 70% ethanol before adding PI. Interestingly, the FACSAria 1 
cell sorting machine used could detect several red fluorophores in 4 different 
channels: PerCp-Cy5; Texas Red; APC and PE-A. HYP and PI showed a 
strong fluorescent signal in the form of a histogram peak in the: PerCp-Cy5; 
Texas Red and APC channels.  
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PI showed a strong positive fluorescence signal in the PE-A channel but HYP 
exhibited a minimal signal in the PE-A channel (Figure 2.6.1) as the number 
of positive events in the PE-A channel for HYP-PDT treated Fb, Mc and Kc 
was: 15.1%; 6.09% and 34% respective (Figure 2.6.1). However, the 
percentage of HYP negative events in the PE-A channel was significantly 
higher in: Fb (84.9%); Mc (93.9%) and Kc (66%). This suggested that HYP 
does not exude significant fluorescence in the PE-A channel which is also 
justified by the fluorescence emission peak of HYP (600-640nm) not 
corresponding to the emission peak of the PE–A channel (667nm). 
Furthermore, the mean fluorescent intensity of PI in the PE-A channel was 
measured (Table 2.6.1) as: 12.9; 3.1 and 16.1 fold higher than HYP mean 
fluorescent intensities in the PEA channel in Fb, Mc and Kc respectively 
(Table 2.6.1).  
 
Therefore, we established that PI fluorescence intensity can be recorded 
using the PE-A channel due to the minimal overlap of HYP and PI red 
fluorescence in this channel and that we can indeed use PI to sort HYP-PDT 
treated cells that have compromised cell membranes.  
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A)   
 
B)  
 
 
C) 
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Figure 2.6.1: Percentage of positive and negative events in the PE-A (red) 
channel of HYP-PDT treated Fb (A); Mc (B) and Kc (C) represented as a 
histogram 
 
 
 
 
Table 2.6.1: Mean Fluorescent Intensities of the PE-A (red) Channel 
 Fb Mc Kc 
PI Treated 597 71.9 1798 
HYP Treated 46.2 23.1 112 
Ratio: PI/ HYP 12.9 3.1 16.1 
PI - HYP 550.8 48.8 1686 
 
 
 
2.7. Data Analysis 
Graphpad Prism (Version 5, Graphpad Software Inc.) was employed for data 
analysis of raw data. Raw data was normalized taking into account the mean 
and standard error mean (mean± SEM) and statistical differences were 
elicited using a one way ANOVA and Dunnet multiple comparison post-test. 
A One way ANOVA with Bonferroni post-tests was used to compare groups 
of data sets when comparing different cell types to each other. P-values less 
than: 0.05; 0.01 and 0.001 indicated significantly different values. 
 
 
 
 
 
56 
 
 
 
 
2.8. Methods Summary 
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Chapter 3: Results 
3.1 Growth Dynamics of Primary Human Skin Cells 
In order to establish the growth dynamics of pure primary human keratinocyte 
(Kc), fibroblast (Fb) and melanocyte (Mc) monocultures, growth curves were 
performed over a period of 7 days. Once pure cultures had been obtained 
(See Section 2.1.1), 5x104 Fb and Mc were seeded on Day 0 and counted on 
days: 1; 3; 5 and 7. Kc (1.5x105) were seeded on Day 0 and counted on 
days: 2; 3; 5 and 7.  
 
Kc exhibited a poor seeding efficiency of 58% as 1.5x105 cells were seeded 
on day 0 which reduced to 8.7x104 cells on day 2 (Figure 3.1.1). However, 
the Kc grew at an improved rate (Figure 3.1.1) and grew exponentially from 
day 3 (2.57x105 cells) through today 7 (7.27x105 cells). In contrast, both Fb 
and Mc seeded well yielding a seeding efficiency of 100% (5x104) and 72% 
(3.6x104), respectively.  Both cell types adopted a similar growth profile over 
7 days (Figure 3.1.1) exhibiting cell numbers of 8.4x104; 2.22x105; 2.38x105 
Fb and 5.3x104; 1.33x105; 1.86x105 Mc on days 3; 5 and 7, respectively 
(Figure 3.1.1). Therefore both Mc and Fb demonstrated a short lag phase 
followed by an exponential phase that proceeded to plateau from day 5 
onwards (Figure 3.1.1). This occurred as a result of contact inhibition as Fb 
and Mc were vey confluent (>80%) when 35mm dishes were viewed with 
light microscopy.  
 
The doubling time (Table 3.1.1), which is the time taken for cells to double in 
number during the exponential growth phase, was estimated visually from the 
graph for each skin cell type. The doubling time for Kc, Mc and Fb was ±2; ±3 
and ±1.5 days, respectively (Table 3.1.1). Seeing that the doubling is 
indicative of cell proliferation, as cells with a smaller doubling time a higher 
growth rate; Fb had the fastest growth rate compared to Mc and Kc (Table 
3.1.1). However, Kc had a slower growth rate than Fb but a faster growth rate 
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than Mc (Figure 3.1.1). Mc had the slowest growth rate compared to both Fb 
and Kc (Table 3.1.1).  
 
 
Figure 3.1.1: Growth curves of primary human skin cells over a period of 7 
days.  Doubling time of Kc, Fb and Mc: ± 2 days; ± 1.5 days and ± 3 days, 
respectively. (*** = p < 0.001)  (Mean; SEM) (n=3) 
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Table.3.1. 1 Characteristics of Different Primary Human Skin Cells 
Cell Type Phase Contrast Image Morphology Doubling 
Time 
(Days) 
Kc 
 
Large, 
tightly 
packed, 
cobblestone 
shaped 
±  2 
Mc 
 
Small, 
round, 
bipolar 
dendrites 
± 3 
Fb 
 
Spindle 
shaped 
± 1.5 
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3.2 Cell Viability 24 Hours Post HYP-PDT 
Having established the seeding efficiencies and growth dynamics of primary 
human skin cells, we investigated the effects of hypericin induced PDT (HYP-
PDT) on cell viability. The XTT cell viability assay (Roche) was carried out 24 
hours post-treatment.  
 
Fb, Mc and Kc were treated with a range of HYP concentrations (0.25µM; 
0.5µM 1µM; 2µM; 3µM; 4µM) in the dark which displayed no significant effect 
on cell viability in any of the 3 cell types compared to the vehicle control 
(Figure 3.2.1 A1; B1; C1; D); thus showing that HYP does not have a 
cytotoxic effect in the dark in these skin cells. However, activated HYP-PDT 
induced a dose-dependent response in Fb (Figure 3.2.1 A2; D) and a 
significant difference (p<0.001) in cell viability compared to the vehicle 
control, following different doses of HYP-PDT:  1µM (56%); 2µM (48%); 3µM 
(33%) and 4µM (34%). The LD50 is indicative of sensitivity to a 
drug/treatment with a smaller LD50 indicating a greater susceptibility to a 
treatment/drug. The LD50 for HYP-PDT treated Fb occurred at 1.75µM HYP-
PDT (Figure 3.2.1 A2; D).  
 
In Mc, (Figure 3.2.1 B2; D), HYP-PDT induced a significant difference in cell 
viability compared to the vehicle control following doses: 2µM (60%) (p< 
0.05); 3µM (61%) (p< 0.05); 4µM (38%) (p< 0.001) HYP-PDT (Figure 3.2.1 
B2; D).  Interestingly, the LD50 for Mc occurred at 3.5µM HYP-PDT; which is 
a higher dose than the dose required to reach the LD50 for Fb. HYP-PDT 
induced an initial significant difference (p< 0.05) in cell viability (79%) in Kc at 
a dose of 4µM HYP-PDT (Figure 3.2.1 C1; D). Since 4µM HYP-PDT was the 
highest dose with which human skin cells were treated, the LD50 for Kc 
occurs at a greater dose than 4µM HYP-PDT; making Kc the least 
susceptible skin cells to HYP-PDT. 
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Furthermore, these different cytotoxic profiles were confirmed statistically 
(Figure 3.2.1 D) as the cell viability of Fb and Kc was significantly different at: 
1µM (p< 0.05); 2µM (p<0.05); 3µM (p< 0.001) and 4µM (p< 0.01) HYP-PDT. 
Furthermore, a significant difference between Mc and Kc occurred at a dose 
of 4µM (p<0.05) HYP-PDT (Figure 3.2.1 D). Therefore, HYP-PDT induces 
different cell viability effects in different human skin cells: Fb being the most 
susceptible, Kc being the least susceptible and the Mc being more 
susceptible than Kc but less sesceptiable than Fb 24 hours post HYP-PDT. 
 
 
A1) 
 
A2) 
 
 
 
B1)
 
 
B2) 
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C1) 
 
 
 
 
 
C2) 
 
D) 
 
Figure 3.2.1: Cell viability assessed using the XTT cell viability assay at 24 
hours in: Fb treated with HYP and no light (A1); Fb treated with HYP-PDT (A2); 
Mc treated with HYP and no light (B1); Mc treated with HYP-PDT (B2); Kc 
treated with HYP and no light (C1); Kc treated with HYP-PDT (C2) and skin 
cells (all types) treated with HYP-PDT (D). VC= vehicle control. LC= light 
control.  
LD50 = dotted blue line.  (*=p < 0.05; **= p < 0.01; ***= p < 0.001) (Mean; SEM) 
(n=3). 
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3.3 Cell Morphology 24 Hours Post HYP- PDT 
Once the cytotoxic profiles of primary human skin cells in response to HYP-
PDT had been established, we were interested in the effects of a non-lethal 
and lethal dose of HYP-PDT on cell morphology. Based on the cytotoxic 
profiles, Fb and Mc were treated with a non-lethal (1µM) and a lethal dose 
(3µM) of HYP-PDT. However, Kc were treated with the highest HYP-PDT 
doses (3µM and 4µM) as the lethal dose for Kc did not occur in our HYP-PDT 
concentration range. Thereafter, cells were stained with Hoechst nuclear dye 
and viewed using phase and fluorescent microscopy 24 hours post HYP-
PDT.  
 
Phase contrast images of Fb (left hand panel, Figure 3.3.1. A1; B1; C1; E1) 
revealed no morphological changes in Fb which were treated with light or 
HYP (1µM and 3µM) compared to the untreated control. However, a change 
in morphology was evident in treated Fb (1µM and 3µM HYP-PDT) (left hand 
panel Figure 3.3.1 D1; F1). Morphological alterations included: cell shrinkage 
or swelling and pronounced vacuolation in the cytoplasm (left hand panel 
Figure 3.3.1 D1; F1, see white arrows), but no evidence of apoptotic nuclei 
was observed. 
 
Furthermore, the corresponding fluorescent images (right hand panel Figure 
3.3.1 D2; F2, see white arrows) show perinuclear localization of HYP being 
displayed as red punctae. Although Hoechst stained nuclei (right hand panel 
Figure 3.3. D2; F2) appeared smaller 24 hours post HYP-PDT, HYP was 
excluded from the nucleus in Fb.  
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Figure 3.3.1: Fb stained with Hoechst nuclear dye (blue) and HYP (red) 24 
hours post HYP-PDT. Phase contrast images on the left hand panel: white 
arrows pointing to vacuoles with corresponding fluorescent images on the 
right hand panel: white arrows pointing to HYP punctae. Untreated Control (A1 
+ A2); light control (B1 + B2); 1µM HYP (C1+ C2); 1µM HYP-PDT (D1 + D2); 3µM 
HYP (E1 + E2); 3 µM HYP-PDT (F1 + F2). Magnification = 400X. (n=2) 
 
 
In Mc, phase contrast microscopy (left hand panel Figure 3.3.2 B1; C1; E1)  
did not exhibit morphological changes 24 hours post-treatment with HYP 
(1µM and 3µM) and light; as Mc looked similar to the bipolar, elegant cells 
with long slender dendrites observed in the untreated control (left hand panel 
Figure 3.3.2 B1). However, Mc which were treated with 1µM HYP-PDT (left 
hand panel Figure 3.3.2 D1) had retracted dendrites and had shrunk 
significantly with clear visual evidence of damaged cell membrane and 
cytoplasmic vacuoles (left hand panel Figure 3.3.2 D1, see white arrows). 
E1  E2 
F1 F2 
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Interestingly, Mc which were treated with 3µM HYP-PDT exhibited slight 
dendrite shrinkage and cytoplasmic vacuolation but maintained cell integrity 
(left hand panel Figure 3.3.2 F1), see white arrows.  
 
The corresponding fluorescent images of Mc (right hand panel Figure 3.3.2 
D2; F2, see white arrows) stained with Hoechst nuclear dye showed HYP 
localization in the cytoplasm with HYP aggregates, resembling bright red 
punctae. Similarly to the Fb, there was no evidence of HYP accumulation in 
melanocyte nuclei (right hand panel Figure 3.3.2 D2; F2) and there was no 
evidence of apoptotic nuclei with phase microscopy (left hand panel Figure 
3.3.2 D1; F1).  
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Figure 3.3.2: Mc stained with Hoechst nuclear dye (blue) and HYP (red) 24 
hours post HYP-PDT. Phase contrast images on the left hand pane: white 
arrows pointing to vacuoles with corresponding fluorescent images on the 
right hand panel: white arrows pointing to HYP punctae. Untreated Control (A1 
+ A2); light control (B1 + B2); 1µM HYP (C1+ C2); 1µM HYP-PDT (D1 + D2); 3µM 
HYP (E1 + E2); 3 µM HYP-PDT (F1 + F2). Magnification = 400X. (n=2) 
 
 
Despite having been treated with the highest HYP-PDT doses (3µM and 
4µM), primary human Kc looked unaffected and remained 80-90% confluent 
(left hand panel, Figure 3.3.3 D1; F1). Furthermore, Kc maintained cell shape 
and integrity, looking very similar to the untreated control (left hand panel 
Figure 3.3.3 A1). At 4µM HYP-PDT exposure they did however display 
minimal evidence of cytoplasmic vacuolation (left hand panel Figure 3.3.3. 
F1, see white arrows). 
 
E1  E2  
F1 F2 
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The corresponding fluorescent images (right hand panel, Figure 3.3.3) of Kc 
had some blue background fluorescence possible due to antifade absorbing 
the Hoechst dye but blue healthy nuclei were evident. HYP localization in Kc 
was also perinuclear and red HYP aggregates distinguishable by red 
cytoplasmic punctae were also visible (right hand panel Figure 3.3.3 D2; F2, 
see white arrows). 
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Figure 3.3.3: Kc stained with Hoechst nuclear dye (blue) and HYP (red) 24 
hours post HYP-PDT. Phase contrast images on the left hand panel: white 
arrows pointing to vacuoles with corresponding fluorescent images on the 
right hand panel:  white arrows pointing to HYP punctae. Untreated Control 
(A1 + A2); light control (B1 + B2); 3µM HYP (C1+ C2); 3µM HYP-PDT (D1 + D2); 
4µM HYP (E1 + E2); 4µM HYP-PDT (F1 + F2).  Magnification = 200X (n=3) 
 
 
Therefore, both non-lethal and lethal doses of HYP-PDT induced distinct 
morphological changes, 24 hours post treatment, in Fb and Mc. However, the 
highest HYP-PDT doses did not induce distinct morphological changes in Kc. 
Interestingly, in all 3 cell types, HYP was excluded from the nucleus at the 24 
hour time point. 
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3.4 Intracellular ROS levels 30 Minutes Post HYP-PDT 
HYP induces its primary effect through production of intracellular ROS. 
Cellular damage is often dependent on the amount of ROS generated. It is 
therefore, necessary to quantify the HYP-PDT induced ROS. Intracellular 
ROS production was evaluated, 30 minutes post HYP-PDT, because HYP-
PDT causes a cytotoxic response via consequential ROS once HYP is 
activated with light. 
 
A fluorescence based ROS assay was used to measure intracellular ROS 
levels, 30 minutes post HYP-PDT, which employed the non-fluorescent probe 
DCF-DA that is cleaved to a fluorescent product by ROS. In order to prevent 
DCF-DA intracellular saturation, 5µM; 10µM and 20µM DCF-DA was tested 
using HYP-PDT (1µM and 3µM) treated Fb (Figure 3.4.1 A; B; C) and 5µM 
DCF-DA was identified as the optimum concentration for this assay.  
 
Once we had optimized this assay, intracellular ROS levels were measured 
30 minutes post HYP-PDT in all the primary cell types. A significant 3.8 fold 
increase (Figure 3.4.1 D) (p< 0.05) in ROS levels (Figure 3.4.1 D) occurred in 
Fb 30 minutes at a dose of 3µM HYP-PDT (Figure 3.4.1 D). However, a 
significant difference in intracellular ROS levels did not occur in Kc and Mc 
(Figure 3.4.1 D) post HYP-PDT.  
 
Furthermore, intracellular ROS levels in Fb were significantly different 
(p<0.001) to intracellular ROS levels in Mc and Kc at a dose of 3µM HYP-
PDT (Figure 3.4.1 D, see box). This correlated with the Fb being the most 
sensitive to HYP-PDT which was confirmed by cell viability and cell 
morphology analysis. Interestingly, intracellular ROS levels in Mc and Kc 
were not significantly different to each other post HYP-PD 
A) B) 
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Figure 3.4.1: Intracellular ROS levels 30 minutes post HYP- PDT in Fb treated 
with 5µM H2DCF-DA (A); Fb treated with 10µM H2DCF-DA (B); Fb treated with 
20µM H2DCF-DA (C); all skin cell types treated with 5µM H2DCF-DA (D). VC= 
vehicle control; LC= light control; 3H = 3µM HYP; 3H+L = 3µM HYP-PDT. 
(p=* < 0.05; p= *** <0.001) (Mean; SEM) (n>3) 
 
 
 
 
 
 
 
3.5 Cell Death Analysis 24 Hours Post HYP-PDT 
Even though apoptotic visualization was attempted with phase and 
fluorescent microscopy, Fluorescent activated cell sorting (FACS) is the 
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preferred method due sensitivity and accuracy. FACS was carried out 24 
hours post HYP-PDT using Annexin V-FITC, an early apoptosis marker, and 
PI which is indicative of cell membrane integrity. Apoptosis analysis via 
FACS is sensitive and accurate because Annexin V-FITC measures 
phosphatidylserine externalization and PI is excluded by live cells with intact 
cell membranes. Therefore, different cell populations can be represented 
according to the 4 quartiles shown by the dot plot example in (Figure 3.5.1 
A): cells in quartile 1 (Q1) are dead but not via apoptosis or necrosis; cells in 
quartile 2 (Q2) are necrotic; cells in quartile 3 (Q3) are undergoing early 
apoptosis and cells in quartile 4 (Q4) are viable.  
 
Once different populations of Fb had been separated 24 hours post HYP-
PDT, using FACS (Figure 3.5.1B); a significant (P<0.001) early apoptotic 
population (64%) was evident after treatment with 3µM HYP-PDT. However, 
a smaller, significant (p< 0.05) early apoptotic Mc population (20%) was 
prominent as a result of 3µM HYP-PDT (Figure 3.5.1 C) treatment. 
Interestingly, 3µM HYP treatment in the dark resulted in a significant (p< 
0.05) early apoptotic (15%) Kc population (Figure 3.5.1 D) but 3µM HYP-PDT 
did not result in a significant early apoptotic Kc population. Furthermore, 
there were no significant necrotic cell populations in any of the skin cell types 
in the controls nor post HYP-PDT. Therefore, HYP-PDT induces a cytotoxic 
effect which results primarily in apoptotic cell death in Fb and Mc but not in 
Kc. 
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Figure 3.5.1: Cell death analysis 24 hours post HYP- PDT evaluated with FACS 
analysis using Annexin V–FITC and PI represented by the dot plot of cell 
populations and the 4 quartiles (A); Fb (B);  Mc (C) and Kc (D). Red = viable 
cells. Black = early apoptotic cells. White = necrotic cells. 
(*= p<0.05; ** = p < 0.01) (Mean; SEM) (n>3) 
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Chapter 4: Discussion: 
Photodynamic therapy (PDT) is a promising cancer treatment modality which 
has been successful in the treatment of non-melanoma skin cancer (NMSC), 
especially basal cell carcinoma (BCC) but it’s effectiveness in the treatment 
of squamous cell carcinoma (SCC) and melanoma skin cancer is currently 
being investigated, by our group and others (Agostinis et al. 2011; Braathen 
et al. 2007; Zhao & He 2010; Davids & Kleemann 2011) Our group is using a 
plant-based  photosensitiser hypericin (HYP) due to its powerful cytotoxic 
effects in several cancer cells including cervical cancer cells; human myeloid 
leukemia cells; hepatocellular liver carcinoma cells and breast cancer cells 
(Barathan et al., 2013; Ferenc, Solár, Kleban, Mikes, & Fedorocko, 2010; 
Sacková, Fedorocko, Szilárdiová, Mikes, & Kleban, 2006; A Vantieghem, 
1998). 
 
An advantage of PDT as a skin cancer therapy includes topical 
administration to  patients (Morton et al., 2008; Ross et al., 2013; Wan & Lin, 
2014; Zhao & He, 2010). Following photosensitiser uptake, light is effectively 
directed onto the  specific area of the skin that contains the cancerous lesion 
(Morton et al., 2008; Ross et al., 2013; Wan & Lin, 2014; Zhao & He, 2010). 
In vivo, a BCC, SCC and a superficial melanoma would be located in the 
epidermis but a SCC occurs predominantly in the basal layer of the epidermis 
(Ahmed et al., 2008; Lauth et al., 2004). In contrast, a  melanoma may be 
superficial (radial and vertical growth phases, RGP and VGP) but also 
possesses the capability of breaching the basement membrane and growing 
vertically to metastasize into the blood vessels (A. J. Miller & Mihm, 2006). 
 
As PDT is a promising topical skin cancer therapy, the surrounding normal 
tissue would be inescapable to photosensitiser exposure and irradiation  
during treatment (Braathen et al., 2007; Svanberg et al., 1994; Wang, Wang, 
Guo, & Xu, 2008; Zeitouni, Oseroff, & Shieh, 2003). It is therefore important 
to know how these cells are affected by treatment as they, being in the same 
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intimate environment, could have bearing on the success or efficacy of the 
treatment being applied. This is known as the “bystander effect”. With this in 
mind, this project investigated the effects of HYP-PDT on normal primary 
human skin cells as representative cell types of the peri-lesional cells to 
measure the bystander effect. Primary human melanocytes (Mc) and 
keratinocytes (Kc) were used as the epidermal cells and primary human 
fibroblasts (Fb) as the dermal representative.  More specifically, the aims of 
this project investigated the in vitro effects of HYP-PDT on normal skin cell 
viability and morphology; intracellular ROS production and the induction of 
apoptosis post treatment.  
 
 
4.1 Primary Human Skin Cells Have Different Growth Dynamics 
in Culture 
Kc, Mc and Fb were isolated from human skin biopsies and neonatal 
foreskins after informed patient consent (see Ethics statement in 
methodology (see section 2.1.1). Thereafter, culture conditions were 
optimized and growth curves performed over a period of 7 days indicated that 
Fb had an excellent seeding efficiency (100%); Mc a good seeding (72%) 
efficiency but Kc exhibited a poor seeding efficiency (58%) by in vitro 
standards. Furthermore, the doubling time during the exponential growth 
phase was: ±2; ±3 and ±1.5 days for Kc, Mc and Fb, respectively. This 
indicated that Fb had the fastest growth rate compared to Mc and Kc; Mc the 
slowest growth rate and Kc grew slower than Fb but faster than Mc during 
the exponential phase. 
 
The slower growth rate of Mc and Kc compared to Fb may have occurred 
because Mc and Kc grow in the same microenvironment, in vivo in the 
epidermis and rely on intercellular cytokines and growth factors for 
proliferation (Hirobe, 2005; Joshi et al., 2007; Nakazawa, Nakazawa, 
Collombel, & Damour, 1995; Valyi-Nagy, Murphy, Mancianti, Whitaker, & 
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Herlyn, 1990). However, Mc and Kc were cultured as monocultures in our in 
vitro system and did not experience intercellular interactions. Although Kc 
had the poorest seeding efficiency out of the 3 skin cells types, they 
proceeded to grow at an improved rate compared to Mc during the 
exponential phase, suggesting that Kc are less dependent on Kc-Mc 
interactions for proliferation compared to Mc. It is known that Mc are 
dependent on Kc derived factors for proliferation and even though Mc 
specific medium (FETI) (Appendix A) has several necessary growth factors 
such as endothelin and basic fibroblast growth factor (bFGF) it does not 
contain every Kc derived growth factor which Mc would be exposed to in vivo 
that may contribute to the suboptimum growth of Mc in vitro (Gordon, 
Mansur, & Gilchrest, 1989; R. Halaban, 1988; Ruth Halaban, 2000; Hirobe, 
2005; Imokawa, Yada, & Miyagishi, 1992). 
 
On the other hand, Fb were cultured efficiently and easily until 90% 
confluent. However they underwent contact inhibition at  ±90% confluency 
and stopped proliferating, which was depicted in the plateau of Fb growth 
rate after day 5 (Abercrombie, 1970; Dietrich, Wallenfang, Oesch, & Wieser, 
1997; Otten, Johnson, & Pastan, 1971). It is possible that Kc and Mc may 
have initiated contact inhibition at a lower confluency, thereby inhibiting 
proliferation and decreasing the growth rate. It was important to establish the 
growth dynamics of primary human skin cells to understand when they were 
in their exponential phase so that adequate conduction of experiments could 
take place with cells growing at their optimum. 
 
 
4.2 HYP-PDT Induces Differential Cytotoxicity in Primary Human 
Skin Cells 
The cytotoxic profile for primary human skin cells 24 hours post-HYP-PDT, 
demonstrated that HYP did not have any cytotoxic effects in the dark in 
primary human skin cells as there was no significant difference in cell viability 
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when cells were treated with various doses of HYP in the dark (0.25µM; 
0.5µM; 0.75µM; 1µM; 2µM; 3µM; 4µM, (Figure 3.2.1). This result was not 
surprising as HYP has a cytostatic effect on cells and not a cytotoxic effect in 
the dark (Krammer & Verwanger, 2012; Kubin et al., 2005). However, 
activated HYP-PDT resulted in a LD50 that varied between HYP-PDT treated 
Fb, Mc and Kc at doses: 1.75µM; 3.5 µM and >4 µM HYP-PDT, respectively. 
As a lower LD50  is indicative of a higher susceptibility to a drug or treatment, 
Fb were the most susceptible cell type to HYP-PDT with Kc being the least 
susceptible and Mc being less susceptible than the Fb but more susceptible 
than the Kc.  
 
As these are indeed all skin cells, the difference in LD50’s between the cells, 
is interesting. Although the pigmentation levels in Mc were not quantified in 
this study, presence of melanin pigment could be a major contributor to the 
protection of melanocytes from ROS-induced PDT. This was corroborated by 
earlier work in melanoma where a decrease in the pigment, led to increased 
susceptibility to HYP-PDT. A further explanation could be that Mc and Kc 
have increased endogenous antioxidant levels (or sophisticated antioxidant 
responses) which may have inferred protection against ROS-based HYP-
PDT induced cytotoxicity. This point ties in with the ultimate function of the Kc 
being the majority cell type of the epidermis, part of the barrier between the 
body and the external environment, and thus the most highly resistant skin 
cell to the HYP-PDT treatment at the 24 hour time point. Moreover, reports 
that the antioxidant levels in the epidermis are greater than the dermis, lend 
further support as to why the Fb were likely to be the most susceptible to 
HYP-PDT (Kohen, 1999; Shindo, Witt, Han, Epstein, & Packer, 1994). 
Additionally, our group established a killing does of 3µM HYP-PDT for human 
melanoma cells (Lester M Davids et al., 2008). We demonstrated in this 
study that 3µM HYP-PDT is indeed cytotoxic to Fb and Mc but not to Kc; it 
was therefore important to further analyze the effects for HYP-PDT using this 
particular dose. 
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4.3 HYP-PDT Induces Distinct Morphological Changes in 
Primary Human Skin Cells 24 hours post Treatment 
HYP-PDT induced distinct morphological changes in both the Mc and the Fb 
whilst sparing the Kc at the lower concentrations Kc only suffered some 
effect when treated with the highest HYP-PDT doses (3µM and 4µM).  
Distinct changes in Fb morphology were apparent at 1µM (non-lethal dose) 
and 3µM (lethal dose) HYP-PDT, with phase contrast microscopy at both 
these doses exhibiting cell shrinkage and cytoplasmic vacuolation. It was 
surprising that Fb morphology was also compromised at both these doses. 
However, we could not compare the morphology of Fb to other studies which 
investigated HYP-PDT effects, as they did not carry out morphological 
analysis (Kashef et al., 2013; Rezusta et al., 2012).  
 
A non-lethal dose (1µM) resulted in morphological changes in Mc; including 
cell shrinkage with associated dendrite retraction. Interestingly, at the lethal 
dose (3µM), Mc looked healthier with few cytoplasmic vacuoles and longer 
dendrites compared to treatment with the non-lethal dose (1µM). One 
explanation for this could be the inherent reaction to upregulate their 
intracellular antioxidant system (catalase, superoxide dismutase and 
glutathione) and increased production of melanin in response to the higher 
oxidative stress doses (Meyskens Jr., Farmer, & Fruehauf, 2001; Swalwell, 
Latimer, Haywood, & Birch-Machin, 2012).This is a well-known response in 
Mc and especially in their cancerous counterparts, melanoma (Hadjur et al., 
1996; Picardo et al., 1996). Perhaps a tolerance to the HYP-PDT doses exist 
somewhere between 1µM and 3µM. Although this response was not 
quantified in this project, it would be intriguing to quantitatively measure it in 
the future.   
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Although 3µM HYP-PDT did not induce any morphological changes in Kc; 
few cytoplasmic vacuoles were evident with phase microscopy at a dose of 
4µM HYP-PDT but cell integrity and shape was maintained. This was not 
surprising as 4µM HYP-PDT induced an initial significant difference in cell 
viability (79%) (p< 0.05) in these cells compared to the vehicle control.  
 
 
4.4 HYP Localizes Perinuclearly in Primary Human Skin 
Cells 
The enigma of why hypericin does not enter the nucleus and effect damage 
is ongoing and it seems in agreement with published literature that  HYP 
localization in the nucleus occurs at doses exceeding 20µM hypericin or after 
incubation time exceeding 8 hours (Agostinis et al., 2002; Krammer & 
Verwanger, 2012; Theodossiou et al., 2009). In our system, fluorescent 
microscopy revealed perinuclear localization of HYP in distinct aggregates in 
all three cell types at a 24 hour time point. Furthermore, Kc staining with 
Hoechst nuclear dye could be improved by viewing cells immediately after 
staining without adding antifade to the mowiol because the antifade absorbed 
the Hoechst nuclear dye and caused a hazy deposition which was observed 
on the fluorescent images. Further co-localization experiments using confocal 
microscopy will need to be performed in order to determine exactly in which 
organelles HYP is localizing.  
 
 
4.5 HYP-PDT Increased Intracellular ROS Levels in Fb but 
not in Kc or Mc 
Since HYP-PDT induces cytotoxic damage via ROS production in the vicinity 
of activated HYP localization, intracellular ROS production was evaluated in 
Fb, Mc and Kc, 30 minutes post HYP-PDT. In Fb, a significant 3.8-fold 
increase in intracellular ROS correlated with the distinct morphological 
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changes and cell viability (33%) observed 24 hours post 3µM HYP-PDT. 
However, there was no significant intracellular ROS production in Mc and Kc 
at a 3µM HYP-PDT dose. Interestingly, although Mc were more susceptible 
to 3µM HYP-PDT than Kc, there was no significant difference in intracellular 
ROS levels between these two cell types, which may be attributed to the 
intracellular presence of melanin. Melanin is known to act as a ROS 
scavenger and “mop” up intracellular ROS when pigmented cells are 
oxidatively stressed (Chedekel & Zeise, 1999; Sander, Chang, Hamm, 
Elsner, & Thiele, 2004; Swalwell et al., 2012).  
 
The insignificant intracellular ROS observed in Kc post treatment correlated 
with their resistance to 3µM HYP-PDT which was depicted by cell viability 
and cell morphology analysis. Since Mc transfer melanin to Kc, melanin may 
have protected Kc from ROS as melanin granules are situated around the 
nucleus in the cytoplasm, although the melanin content in Kc is much lower 
than in Mc (Van Den Bossche, Naeyaert, & Lambert, 2006; Wood et al., 
1999). Furthermore, Kc may require longer than 4 hours for HYP uptake 
because HYP-PDT may not have induced a cytotoxic effect in Kc if 
insufficient HYP accumulated intracellularly upon light activation, which would 
have generated minimal 1O2 and therefore the oxidative stress would have 
also been minimal. We chose a 4 hour incubation period for this study, as 
this was the optimized HYP uptake time determined by our group for human 
melanoma cells. However, we did not investigate HYP uptake time for Kc and 
this may be interesting to explore further when determining the LD50 for Kc. 
Early Stage Apoptosis Occurred in Primary Fibroblasts and Melanocytes 24 
hours post HYP-PDT Treatment. Seeing that an increase in intracellular ROS 
can lead to apoptosis, we in investigated whether HYP-PDT induced ROS 
can cause apoptosis in Fb, Mc and Kc (Martin & Barrett, 2002; Simon, Haj-
Yehia, & Levi-Schaffer, 2000; Tan, Wood, & Maher, 2002). Despite there 
being no evidence of apoptotic nuclei in any of the 3 skin cell types during 
morphological analysis of HYP-PDT treated skin cells, more sensitive 
methods were needed to assess apoptosis. The cells viewed 24 hours post 
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HYP-PDT were adherent cells either at the early stage of cell death or 
resistant to the treatment as necrotic and late apoptotic cells would have 
lifted and been lost during the staining process. However, apoptotic 
(fragmented) nuclei is a characteristic of late stage apoptosis which would 
result in cells rounding up, lifting and inevitably being washed off the glass 
slides during the staining protocol (Gerschenson & Rotello, 1992; Saraste, 
2000). 
 
We therefore assessed apoptosis using fluorescent activated cell sorting 
(FACS) with the fluorophores Annexin V-FITC and PI - direct measures of 
early apoptosis and plasma cell membrane integrity, respectively. FACS 
analysis confirmed a significant early apoptotic Fb (64%) (p<0.001) and Mc 
(20%) (p<0.05) populations, 24 hours post 3µM HYP-PDT. The significant, 
majority early apoptotic Fb population correlated with the fibroblasts being 
most susceptible to HYP-PDT and the significant increase in intracellular 
ROS production. This result correlated with literature stipulating that HYP-
PDT causes accumulation of intracellular ROS which can lead to cell death 
via apoptosis and has been shown in several cancer cells such as cervical 
cells, glioblastoma cells, melanoma cells and T-lymphocyte leukemic cells 
(Agostinis et al., 2002; Barathan et al., 2013; Lester M Davids et al., 2008; 
Huntosova et al., 2012; Kiesslich et al., 2006; Krammer & Verwanger, 2012; 
Schempp, Simon-haarhaus, Termeer, & Simon, 2001; Theodossiou et al., 
2009; A Vantieghem, 1998; Annelies Vantieghem et al., 2007). However, to 
our knowledge, no studies have shown apoptosis occurring in Fb and Mc 
post HYP-PDT and since this is ongoing research, further experiments using 
western blotting techniques will be conducted to confirm apoptosis protein 
expression.  
 
Interestingly, there was no significant intracellular ROS measured in Mc, but 
there was evidence of early stage apoptosis 24 hours post 3µM HYP-PDT. 
This indiscretion may have occurred due to apoptosis analysis being 
conducted at a much later time point (24 hours) than intracellular ROS which 
84 
 
was measured 30 minutes post HYP-PDT. By this time, the intracellular ROS 
levels may have overwhelmed the Mc antioxidant system and caused 
intracellular organelle damage (Engel, Ryan, 2006; Matés, Segura, Alonso, & 
Márquez, 2008; Schallreuter, 2007). The possible protective effect of melanin 
HYP-PDT and endogenous antioxidants in pigmented cells are of particular 
interest to our lab and are currently being investigated. 
 
Surprisingly, treatment with 3µM HYP in the dark resulted in a significant 
15% (p< 0.01) early apoptotic Kc population, which did not correlate to the 
cell viability response to HYP treated Kc in the dark. However, HYP in the 
dark has been shown to have effects on heat shock protein 90 (Hsp 90) 
ubiquitinylation in a murine mammary adenocarcinoma cell line and a human 
SCC cell line, which has been suggested to lead to mitotic induced cell death 
(Blank, Mandel, Keisari, Meruelo, & Lavie, 2004). Hsps are a family of 
proteins that defend cells from external stress and Hsp 90  is stimulated in 
stressed Kc (Holland, Roberts, Wood, & Cunliffe, 1993; Jäättelä, 2009; 
Maytin, 1992). It could be interesting to investigate the effect of HYP-PDT on 
Hsp 90 in Kc as this will provide further information on how Kc are coping 
with HYP-PDT treatment.   
 
 
4.6 Conclusions and Future Directions 
The data collected during this project displayed the differential response of 
primary human skin cells to HYP-PDT (Figure 4.6.1). To date, there have 
been no studies which have investigated the effects of a HYP-PDT 
melanomas-killing dose on all 3 primary human skin cell types. We found that 
3µM HYP-PDT is cytotoxic to Fb (Figure 4.6.1) and to a lesser extent Mc but 
the highest HYP-PDT dose we tested, was not cytotoxic to Kc (Figure 4.6.1). 
This was a favorable finding as Kc are the predominant cell type in the 
epidermis and are therefore most at risk during PDT of a skin cancer that 
resides in the epidermis. Future directions include validating HYP-PDT-
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induced apoptosis protein pathways induced in normal skin via protein 
expression of key apoptotic proteins such as Caspases 3; 7 and 8; B-cell 
lymphoma 2 (Bcl2) and pro-apoptotic protein BAK using western blot analysis 
(Figure 4.6.1). Furthermore, we intend to investigate the role of melanin and 
endogenous antioxidants in skin cancer cells with regards protecting the cells 
from HYP-PDT (Figure 4.6.1) 
 
 
 
 
Figure 4.6.1: Summary of results (differential response to HYP-PDT by primary 
human skin cells and future directions that have stemmed from this project 
 
 
Additionally, we would like to further asses the effects of HYP-PDT on Mc 
and Kc co-cultures which are exposed to Fb and skin cancer cell conditioned 
media; resembling the in vivo environmental conditions of skin cells in the 
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epidermis (Figure 4.6.1). Moreover,  we intend to assess the effects of HYP-
PDT on a 3D in vitro skin equivalent model that includes melanoma cells and 
recapitulates the microenvironment of a melanoma (Figure 4.6.1); as there is 
evidence that cancer cells and the tumor microenvironment communicate via 
paracrine signaling enabling the tumor microenvironment to contribute to 
tumor progression, proliferation, metastasis and resistance to treatment 
(Celli, 2013; Junttila & de Sauvage, 2013; Maes, Rubio, Garg, & Agostinis, 
2013; Quail & Joyce, 2013). Therefore, it would be worthwhile to investigate 
the effects of HYP-PDT on a skin cancer microenvironment and to validate 
the specificity of HYP-PDT for skin cancer cells. 
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Appendix A: Solutions 
1.12.1. Separating Epidermis and Dermis from Skin 
Tissue  
 
Work in a petri-dish in a drop of 1xPBS and antibiotics  
Gently grasp epidermis layer with forceps tip  
Hold Dermis in place with tweezers  
Gently pull the epidermis away from the dermis in one movement  
1.13.   
1.13.1. Dulbecco’s Modified Eagle’s Medium (DMEM) 
(pH 7.4, 1L) 
 
DMEM powder 27.06g 
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NaHCO3 7.4g 
Autoclaved ddH20 qs 
Sterilize through a 0.2µm filter and store in aliquots at 4°C  
  
1.13.2. Fetal Calf Serum (FCS) (500ml)  
FCS 500ml 
Heat inactivate at 56°C (water bath) for 20 minutes  
Allow to cool and store in aliquots at -20°C  
  
1.13.3. Penicillin (100U/ml)/Streptomycin (100µg/ml)  
Penicillin (1662U/mg) 3g 
Streptomycin (750U/mg) 5g 
ddH20 100ml 
Sterilize through a 0.2µm filter and store aliquots at -20°C  
  
1.13.4. Trypsin (0.05%) Supplemented with 0.1% 
Glucose (100ml)  
(pH 7.3) 
 
Trypsin (BD Biosciences, USA) 0.05g 
Glucose 0.1g 
ddH2O 100ml 
sterilize through a 0.2µm filter and store at -20°C  
  
1.13.5. Complete Fibroblast Medium (400ml) (pH 7.4)  
FCS (100%) 40ml 
Penicillin/streptomycin (100x) 4ml 
DMEM qs 
sterilize through a 0.2µm filter and store at 4°C  
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1.13.6. Ham’s F10 (500ml)   
Hams F10 powder 4.93g 
NaHCO3 0.2g 
sterilize through a 0.2µm filter and store at 4°C  
  
1.13.7. Complete Melanocyte Specific Medium (FETI) 
(500ml) (p.H 7.4) 
 
FCS (Lonza) 10ml 
Ultroser G 5ml 
bFGF (10µg/ml) 100µl 
Endothelin (10µg/ml) 100µl 
TPA (40µM) 200µl 
IBMX (5mM) 5ml 
Penicillin/Streptomycin  5ml 
Ham’s F10 ds 
sterilize through a 0.2µm filter and store at -20°C  
  
1.13.8. Complete Keratinocyte Specific Medium 
(KSFM) Gibco® (500ml)  
 
KSFM (synthetically defined keratinocyte medium) 500ml 
Bovine pituitary extract (BPE) Gibco® 25mg 
Epidermal growth factor (EGF) Gibco ® 2.5µg/ml 
Penicillin/streptomycin (100X) 5ml 
sterilize through a 0.2µm filter and store at -20°C  
  
1.13.9. Ham’s F12 (700ml)  
Ham’s F12 Gibco® 1.86g 
ddH2O sq 
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sterilize through a 0.2µm filter and store at 4°C  
 
1.13.10. GREEN’S Medium for Keratinocytes 
(400ml) (pH 7.3) 
 
Ham’s F12 100ml 
Insulin (3.85mg/ml) 500µl 
Hydrocortisone (0.2mg/ml) 800µl 
Cholera Toxin (1x10-7M) 400µl 
T/T3 (5mg/ml) 400µl 
EFG (10µg/ml) 400µl 
Penicillin/ Streptomycin (100X) 4ml 
Gentamycin (10mg/ml, 1%) 8ml 
Sodium Bicarbonate (7.5% a.q.) 4ml 
Hepes Buffer (1M) (pH 7.3) 8ml 
FCS (Lonza) (IH) 40ml 
Ham’s F12 sq 
sterilize through a 0.2µm filter and store at -20°C  
  
1.13.11. Trypsin/ EDTA (100ml)  
Trypsin (0.05%) (BD, Biosciences, USA) 0.05g 
EDTA anhydrous (0.02%) (Sigma-Aldrich, USA) 0.02g 
ddH2O 100ml 
sterilize through a 0.2µm filter and store at -20°C  
  
1.13.12. Phosphate Buffered Saline (1xPBS) (pH 
7.4) (1L) 
 
NaCl (0.14M) 8g 
Na2HPO4  (8.8M) 1.26g 
KCl (2.7M) 0.2g 
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KH2PO4 (1.47M) 0.2g 
ddH2O qs 
Autoclave and store at 4°C  
  
1.13.13. Mycoplasma Test (Hoechst Dye)  
Grow cells on coverslips for a period of 7 days without 
antibiotics 
Remove culture medium   
Wash with 1xPBS  
Fix cells with 1ml glacial acetic acid : methanol (1:3) for 6 
mins  
Discard Hoechst and wash cells 3X with 1xPBS 
Mount coverslips onto glass slides in Mowiol  
View slides using fluorescent microscopy  
 
  
  
  
  
  
1.14. Hypericin-Induced Photodynamic Therapy (HYP-
PDT) 
 
1.15.   
1.15.1. Hypericin (HYP) Stock Solution (2mM)  
Hypericin powder 1mg 
Dimethyl sulfoxide (100%) 1ml 
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1.16. Fluorescence Based ROS Assay  
1.17.   
1.17.1. DCF-DA Working Stock Solution 
Preparation (1mM) 
 
DCF-DA (100mM) 10µl 
1xPBS 990µl 
  
1.18. Microscopy Slide Preparation  
1.19.   
1.19.1. 4% Paraformaldehyde (PFA) (100ml)  
PFA (Merck, Germany) 4g 
1xPBS qs 
Heat at 50°C to dissolve and store in aliquots at -20°C  
  
1.19.2. Mowiol   
Mowiol (Sigma-Aldrich, USA) 2.4g 
Glycerol (Merck, South Africa) 6g 
Tris buffer (0.2M) (pH 8.5) 12ml 
ddH2O 6ml 
Stir for a few hours at 50°C  
Centrifuge at 12000 rpm for 20 mins  
Store supernatant in 1ml aliquots at -20  
  
1.20. Fluorescent Activated Cell Sorting (FACS)  
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1.20.1. Hepes Buffer (12mM) (15ml) (pH 7.4)  
Hepes  0.04289g 
ddHO sq 
Make up fresh on the day of FACS experiment  
  
1.20.2. Annexin V-FITC Binding Buffer (13ml)  
Hepes buffer (12mM) 10.833ml 
NaCl (1M) 1.82ml 
CaCl2 (100mM) 325µl 
ddH2O 22µl 
  
1.20.3. Propidium Iodide (PI) (50µg/ml)  
Propidium iodide stock (1mg/ml) 50µl 
ddH2O 950µl 
 
 
